<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>c55725_10k.htm
<TEXT>

<HTML>
<HEAD>
   <TITLE>form10-k.htm -- Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing</TITLE>
</HEAD>

<BODY bgcolor="#ffffff">



<A name="page_1"></A>


<P align="center">
<B><FONT size=2 face="serif">As filed with the Securities and Exchange Commission on November 26, 2008</FONT></B><FONT face="serif"> </FONT></P>
<P align="center">
<B><FONT size=5 face="serif">SECURITIES AND EXCHANGE COMMISSION</FONT></B><br>
<B><FONT face="serif">WASHINGTON, D.C. 20549</FONT></B></P>
<P align="center">
<B><FONT size=5 face="serif">F</FONT></B><B><FONT size=4 face="serif">ORM</FONT></B><B><FONT size=5 face="serif"> 10-K</FONT></B></P>
<P align="center">
<B><FONT face="serif">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF <br>
THE SECURITIES EXCHANGE ACT OF 1934</FONT></B><FONT face="serif"> </FONT></P>
<P align="center">
<B><FONT size=2 face="serif">FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2008&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;COMMISSION
FILE NUMBER 1-4802</FONT></B></P>
<P align="center">
<B><FONT size=5 face="serif">BECTON, DICKINSON AND COMPANY</FONT></B><br>
<B><FONT size=2 face="serif">(Exact name of registrant as specified in its charter)</FONT></B></P>
<TABLE border=0 width=100% cellspacing=0 cellpadding=0>
<TR valign="bottom">
	<TD align=center width=50% nowrap>
<B><FONT  size=2 face="serif">New Jersey</FONT></B>	</TD>
	<TD align=center width=50% nowrap>
<B><FONT  size=2 face="serif">22-0760120</FONT></B>	</TD>
</TR>
<TR valign="bottom">
	<TD align=center width=50% nowrap>
<B><FONT  size=2 face="serif">(State or other jurisdiction of</FONT></B>	</TD>
	<TD align=center width=50% nowrap>
<B><FONT  size=2 face="serif">(I.R.S. Employer</FONT></B>	</TD>
</TR>
<TR valign="bottom">
	<TD align=center width=50% nowrap>
<B><FONT  size=2 face="serif">incorporation or organization)</FONT></B>	</TD>
	<TD align=center width=50% nowrap>
<B><FONT  size=2 face="serif">Identification No.)</FONT></B>	</TD>
</TR>
<TR valign="bottom">
	<TD align=center width=50% nowrap>
<B><FONT  size=2 face="serif">1 Becton Drive</FONT></B>	</TD>
	<TD align=center width=50% nowrap>
<B><FONT  size=2 face="serif">07417-1880</FONT></B>	</TD>
</TR>
<TR valign="bottom">
	<TD align=center width=50% nowrap>
<B><FONT  size=2 face="serif">Franklin Lakes, New Jersey</FONT></B>	</TD>
	<TD align=center width=50% nowrap>
<B><FONT  size=2 face="serif">(Zip code)</FONT></B>	</TD>
</TR>
<TR valign="bottom">
	<TD align=center width=50% nowrap>
<B><FONT  size=2 face="serif">(Address of principal executive offices)</FONT></B>	</TD>
	<TD align=left width=50% nowrap>&nbsp;	</TD>
</TR>
</TABLE>
<BR>
<P align="center">
<B><FONT  size=2 face="serif">(201) 847-6800</FONT></B><br>
<B><FONT  size=2 face="serif">(Registrant&#146;s
telephone number, including area code)</FONT></B></P>
<P align="center">
<B><FONT  size=2 face="serif">Securities registered pursuant to Section 12(b) of the Act: </FONT></B><FONT  face="serif">  </FONT></P>
<TABLE border=0 width=100% cellspacing=0 cellpadding=0>
<TR valign="bottom">
	<TD align=left width=50% nowrap>&nbsp;	</TD>
	<TD align=center width=50% nowrap>
<B><FONT  size=2 face="serif">Name of each exchange on</FONT></B>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=50% nowrap style="border-bottom:1px solid #000000;">
      <div align="center"><B><FONT  size=2 face="serif">Title of each class</FONT></B> </div></TD>
	<TD align=center width=50% nowrap style="border-bottom:1px solid #000000;">
<B><FONT  size=2 face="serif">which registered</FONT></B>	</TD>
</TR>
<TR valign="bottom">
  <TD align=left nowrap style="border-bottom:0px solid #000000;"><div align="center"><font  size=2 face="serif">Common
    Stock, par value &#36;1.00</font><font  face="serif"> </font></div></TD>
  <TD align=center nowrap style="border-bottom:0px solid #000000;"><font  size=2 face="serif">New
    York Stock Exchange</font></TD>
</TR>
</TABLE>
<BR>

<P align="center">
<B><FONT  size=2 face="serif">Securities registered pursuant to Section 12(g) of the Act:</FONT></B><FONT  size=2 face="serif"> <br>
None</FONT><FONT  face="serif"> </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT  size=2 face="serif">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </FONT><FONT  size=2 face="wingdings"> </FONT><FONT  size=2 face="serif"></FONT><FONT  size=2 face="serif">&nbsp;&nbsp;Yes </FONT><FONT  size=2 face="wingdings">x </FONT><FONT  size=2 face="serif">No </FONT><FONT  size=2 face="wingdings">o</FONT><FONT  face="serif"> </FONT></P>
<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT  size=2 face="serif">Indicate by check mark if
  the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. </FONT><FONT  size=2 face="wingdings"> </FONT><FONT  size=2 face="serif"></FONT><FONT  size=2 face="serif">&nbsp;&nbsp;Yes </FONT><FONT  size=2 face="wingdings">o </FONT><FONT  size=2 face="serif">No </FONT><FONT  size=2 face="wingdings">x</FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT  size=2 face="serif">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </FONT><FONT  size=2 face="wingdings"> </FONT><FONT  size=2 face="serif"></FONT><FONT  size=2 face="serif">&nbsp;&nbsp;Yes </FONT><FONT  size=2 face="wingdings">x </FONT><FONT  size=2 face="serif">No </FONT><FONT  size=2 face="wingdings">o</FONT><FONT  face="serif"> </FONT></P>
<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT  size=2 face="serif">Indicate by check mark if disclosure of delinquent filers
  pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant&#146;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any
  amendment to this Form 10-K.</FONT><FONT  size=2 face="serif"> </FONT><FONT  size=2 face="wingdings">o</FONT><FONT  face="serif"> </FONT></P>
<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT  size=2 face="serif">Indicate by checkmark whether the registrant is a large accelerated
  filer, an accelerated filer, or a non-accelerated filer (as defined in Rule 12b-2 of the Act).</FONT> </P>
<P align="center">
<FONT  size=2 face="serif">Large accelerated filer </FONT><FONT  size=2 face="wingdings">x</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT  size=2 face="serif">Accelerated filer </FONT><FONT  size=2 face="wingdings">o</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT  size=2 face="serif">Non-accelerated filer </FONT><FONT  size=2 face="wingdings">o</FONT><FONT  face="serif"> </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT  size=2 face="serif">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). </FONT><FONT  size=2 face="wingdings"> </FONT><FONT  size=2 face="serif"></FONT><FONT  size=2 face="serif">&nbsp;&nbsp;Yes </FONT><FONT  size=2 face="wingdings">o </FONT><FONT  size=2 face="serif">No </FONT><FONT  size=2 face="wingdings">x</FONT></P>
<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT  size=2 face="serif">As of March 31, 2008, the aggregate
    market value of the registrant&#146;s outstanding common stock held by non-affiliates of the registrant was approximately &#36;20,897,758,525.</FONT><FONT  face="serif"> </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT  size=2 face="serif">As of October 31, 2008, 243,115,261 shares of the registrant&#146;s common stock were outstanding.</FONT><FONT  size=1 face="serif"> </FONT></P>
<P align="center">
<B><FONT  size=2 face="serif">Documents Incorporated by Reference</FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT  size=2 face="serif">(1) Portions of the registrant&#146;s Annual Report to Shareholders for the fiscal year ended September 30, 2008 are incorporated by reference into Parts I and II
hereof.</FONT><FONT  face="serif"> </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT  size=2 face="serif">(2) Portions of the registrant&#146;s Proxy Statement for the Annual Meeting of Shareholders to be held February 3, 2009 are incorporated by reference into Part III
hereof.</FONT></P>
<P align="left">&nbsp;</P>
<HR noshade align="center" width="100%" size=4>



<P align="left" style="page-break-before:always"></P><PAGE>
<A name="page_2"></A>

<P align="center">
<B><FONT face="serif">PART I</FONT></B></P>
<P align="left">
<B><FONT size=2 face="serif">Item 1. </FONT></B><B><I><FONT size=2 face="serif">Business.</FONT></I></B></P>
<P align="left">
<B><FONT size=2 face="serif">General</FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Becton, Dickinson and Company (also known as &#147;BD&#148;) was incorporated under the laws of the State of New Jersey in November 1906, as successor to a New York business started in 1897.
BD&#146;s executive offices are located at 1 Becton Drive, Franklin Lakes, New Jersey 07417-1880, and its telephone number is (201) 847-6800. All references in this Form 10-K to &#147;BD&#148; refer to Becton, Dickinson and Company and its domestic
and foreign subsidiaries, unless otherwise indicated by the context. </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD is a medical technology company engaged principally in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used
by healthcare institutions, life science researchers, clinical laboratories, industry and the general public. </FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Business Segments</FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD&#146;s operations consist of three worldwide business segments: BD Medical, BD Diagnostics and BD Biosciences. Information with respect to BD&#146;s business segments is included in Note 15
to the consolidated financial statements contained in the portions of BD&#146;s Annual Report to Shareholders for the fiscal year ended September 30, 2008 attached hereto as Exhibit 13, and is incorporated herein by reference. </FONT></P>
<P align="left">
<I><FONT size=2 face="serif">BD Medical</FONT></I></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD Medical produces a broad array of medical devices that are used in a wide range of healthcare settings. They include many safety-engineered injection, infusion and surgery products. BD
Medical&#146;s principal product lines include needles, syringes and intravenous catheters for medication delivery; prefilled IV flush syringes; and syringes and pen needles for the self-injection of insulin and other drugs used in the treatment of
diabetes; prefillable drug delivery devices provided to pharmaceutical companies and sold to end-users as drug/device combinations; surgical blades/scalpels and regional anesthesia needles and trays; critical care monitoring devices; ophthalmic
surgical instruments; sharps disposal containers; and home healthcare products such as ACE&#174; brand elastic bandages. The primary markets served by BD Medical are hospitals and clinics; physicians&#146; office practices; consumers and retail
pharmacies; public health agencies; pharmaceutical companies; and healthcare workers. </FONT></P>
<P align="left">
<I><FONT size=2 face="serif">BD Diagnostics</FONT></I></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD Diagnostics provides products for the safe collection and transport of diagnostic specimens and instrumentation for analysis across a broad range of infectious disease testing, including
healthcare-associated infections (HAIs). BD Diagnostics&#146; principal products and services include integrated systems for specimen collection; an extensive line of safety-engineered blood collection products and systems; plated media; automated
blood culturing systems; molecular testing systems for sexually transmitted diseases and HAIs; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screenings; and rapid diagnostic assays.
BD Diagnostics serves hospitals, laboratories and clinics; reference laboratories; blood banks; healthcare workers; patients; physicians&#146; office practices; and industrial microbiology laboratories. </FONT></P>
<P align="left">
<I><FONT size=2 face="serif">BD Biosciences</FONT></I></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD Biosciences produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. That
information is used to aid the discovery and development of new drugs and vaccines, and to improve the diagnosis and management of diseases. BD Biosciences&#146; principal product lines include fluorescence-activated cell sorters and analyzers; cell
imaging systems, monoclonal antibodies and kits for performing cell analysis; reagent systems for life sciences research; tools to aid in drug discovery and growth of tissue and cells; cell culture media supplements for biopharmaceutical
manufacturing; and diagnostic assays. The primary markets served by BD Biosciences are research and clinical laboratories; hospitals and transplant centers; blood banks; and biotechnology and pharmaceutical companies. </FONT></P>
<P align="center">
<FONT face="serif">2</FONT></P>

<HR noshade align="center" width="100%" size=4>



<P align="left" style="page-break-before:always"></P><PAGE>
<A name="page_3"></A>

<P align="left">
<B><FONT size=2 face="serif">Acquisitions</FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">On May 12, 2008, BD acquired 100% of the outstanding stock of Cytopeia Inc., a privately-held corporation that develops and markets advanced flow cytometry cell sorting instruments.  The
acquisition advances BD&#146;s position in rapidly emerging areas of cell-based research, such as cell therapy research, stem cell research, drug discovery and development, and marine biology.  See further discussion of this acquisition in Note 3 to
the consolidated financial statements contained in Exhibit 13, which is incorporated herein by reference. </FONT></P>
<P align="left">
<B><FONT size=2 face="serif">International Operations</FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD&#146;s products are
manufactured and sold worldwide. BD&#146;s
operations outside the U.S. are conducted in Canada and in the following
geographic regions: Europe (which includes the Middle East and Africa); Japan;
Asia Pacific (which includes Australia and all of Asia except Japan); and Latin
America (which includes Mexico and Brazil). The principal products sold by BD
outside of the U.S. are hypodermic needles and syringes; insulin syringes
and pen needles; diagnostic systems; BD Vacutainer</FONT><SUP><FONT size=2 face="serif">TM</FONT></SUP><FONT size=2 face="serif"> brand
blood collection products; BD Hypak<SUP>TM</SUP> brand
prefillable syringe systems; infusion therapy products; flow cytometry instruments
and reagents; and disposable laboratory products. BD has manufacturing operations
outside the U.S. in Brazil, Canada, China, France, Germany, India, Ireland, Japan,
Mexico, Pakistan, Singapore, South Korea, Spain, Sweden and the United Kingdom.
Geographic information with respect to BD&#146;s operations is included under
the heading
&#147;Geographic Information&#148; in Note 15 to the consolidated financial statements
included in Exhibit 13, and is incorporated herein by reference. </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Foreign economic conditions
and exchange rate fluctuations have caused the profitability related to foreign
revenues to fluctuate more than the profitability related to domestic revenues.
BD believes its activities in some countries outside the U.S. involve greater
risk than its domestic business due to the factors cited herein, as well as the
economic environment, local commercial and economic policies and political uncertainties.
See further discussion of this risk in Item 1A. Risk Factors. </FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Distribution</FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD&#146;s products are marketed in the U.S. and internationally through independent distribution channels and directly to end-users by BD and independent sales representatives. Sales to a
single U.S. distributor that supplies products from the BD Medical and BD Diagnostics segments to many end-users accounted for approximately 9% of total BD revenues in fiscal 2008. However, the end-users of BD&#146;s products have access to those
products through other distributors, and, as a result, BD believes that sales to this distributor would be replaced largely, if not entirely, by other sales if BD no longer sold products to this distributor. Order backlog is not material to
BD&#146;s business inasmuch as orders for BD products generally are received and filled on a current basis, except for items temporarily out of stock. BD&#146;s worldwide sales are not generally seasonal, with the exception of certain medical
devices in the BD Medical segment and respiratory and flu diagnostic products in the BD Diagnostics segment that relate to seasonal diseases such as influenza. </FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Raw Materials</FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD purchases many different types of raw materials, including plastics, glass, metals, textiles, paper products, agricultural products, electronic and mechanical sub-assemblies and various
biological, chemical and petrochemical products. Certain raw materials (primarily related to the BD Biosciences segment) are not available from multiple sources. In the case of certain principal raw materials that are available from multiple
sources, for various reasons (including quality assurance and cost effectiveness), BD elects to purchase these raw materials from sole suppliers. In other cases where there are regulatory requirements relating to qualification of suppliers, BD may
not be able to establish additional or replacement sources on a timely basis. While BD works closely with its suppliers to ensure continuity of supply, the termination, reduction or interruption in supply of these sole-sourced raw materials could
impact our ability to manufacture and sell certain of our products. </FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Research and Development</FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD conducts its research and development activities at its operating units and at BD Technologies in Research Triangle Park, North Carolina. Substantially all of BD&#146;s research and
development activities are conducted in the U.S. BD also collaborates with certain universities, medical centers and other entities on research and development programs. BD also retains individual consultants to support its efforts in specialized
fields. BD</FONT></P>
<P align="center">
<FONT face="serif">3</FONT></P>

<HR noshade align="center" width="100%" size=4>



<P align="left" style="page-break-before:always"></P><PAGE>
<A name="page_4"></A>

<P align="left">
<FONT size=2 face="serif">spent approximately &#36;396 million, &#36;360 million and &#36;302 million on research and development during the fiscal years ended September 30, 2008, 2007 and 2006, respectively. In addition, BD incurred acquired
in-process research and development charges of &#36;122 million related to the acquisitions of TriPath and Plasso in fiscal year 2007, and &#36;53 million related to the acquisition of GeneOhm in fiscal year 2006. </FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Intellectual Property and Licenses</FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD owns significant intellectual property, including patents, patent applications, technology, trade secrets, know-how, copyrights and trademarks in the United States and other countries. BD is
also licensed under domestic and foreign patents, patent applications, technology, trade secrets, know-how, copyrights and trademarks owned by others. In the aggregate, these intellectual property assets and licenses are of material importance to
BD&#146;s business. BD believes, however, that no single patent, technology, trademark, intellectual property asset or license is material in relation to BD&#146;s business as a whole, or any business segment. </FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Competition</FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD operates in the increasingly complex and challenging medical technology marketplace whose dynamics are changing. Technological advances and scientific discoveries have accelerated the pace
of change in medical technology, and regulation of increasingly more sophisticated and complex medical products is increasing. Companies of varying sizes compete in the global medical technology field. Some are more specialized than BD with respect
to particular markets, and some have greater financial resources than BD. New companies have entered the field, particularly in the areas of safety-engineered devices and in life sciences, and established companies have diversified their business
activities into the medical technology area. Other firms engaged in the distribution of medical technology products have become manufacturers of medical devices and instruments as well. Acquisitions and collaborations by and among other companies
seeking a competitive advantage also affect the competitive environment. In addition, the entry into the market of manufacturers located in China and other low-cost manufacturing locations are creating increased pricing pressures, particularly in
developing markets. Some competitors have also established manufacturing sites or have contracted with suppliers located in these countries as a means to lower their costs.  New entrants may also appear, particularly from these low-cost countries.
</FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD competes in this evolving marketplace on the basis of many factors, including price, quality, innovation, service, reputation, distribution and promotion. The impact of these factors on
BD&#146;s competitive position varies among BD&#146;s various product offerings. In order to implement one of its core strategies&#151;to increase revenue growth by focusing on products that deliver greater benefits to patients, healthcare workers
and researchers&#151;and maintain an advantage in the competitive environment in which it operates, BD continues to make investments in research and development, quality management, quality improvement, product innovation and productivity
improvement. </FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Third-Party Reimbursement</FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Healthcare providers and/or facilities are generally reimbursed for their services through numerous payment systems designed by governmental agencies (e.g., Medicare and Medicaid in the U.S.,
the National Health Service in the U.K., the Joint Federal Committee in Germany, the Commission d&#146;Evaluation des Produits et prestations in France, and the Ministry for Health, Labor and Welfare in Japan), private insurance companies, and
managed care organizations. The manner and level of reimbursement in any given case typically depends on the procedure(s) performed, the final patient diagnosis, the device(s) and/or drug(s) utilized, or a combination of these factors, and coverage
and payment levels are determined at the payer&#146;s discretion. The coverage policies and reimbursement levels of third-party payers may impact the decisions of healthcare providers and facilities regarding which medical products they purchase and
the prices they are willing to pay for those products. Thus, changes in reimbursement level or method may either positively or negatively impact sales of BD products. While BD is actively engaged in promoting the value of its products for payers and
patients, and it employs various efforts and resources to positively impact coverage, coding and payment processes in this regard, it has no direct control over payer decision-making with respect to coverage and adequate payment level for BD
products. Additionally, we expect many payers to continue to explore cost-containment strategies (e.g., comparative effectiveness analyses, so-called &#147;pay-for-performance&#148; programs implemented by various public and private payers, etc.)
that could potentially impact coverage and/or payment levels for current or future BD products. </FONT></P>
<P align="center">
<FONT face="serif">4 </FONT><FONT size=1 face="serif"></FONT></P>

<HR noshade align="center" width="100%" size=4>



<P align="left" style="page-break-before:always"></P><PAGE>
<A name="page_5"></A>

<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">As BD&#146;s product offerings are diverse across many healthcare settings, they are affected to varying degrees by the many payment systems. Therefore, while individual countries, product
lines or product classes may be impacted, BD does not believe that significant changes to any one of these systems would have a material adverse effect on BD. </FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Regulation</FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD&#146;s medical technology products and operations are subject to regulation by the U.S. Food and Drug Administration (&#147;FDA&#148;) and various other federal and state agencies, as well
as by foreign governmental agencies. These agencies enforce laws and regulations that govern the development, testing, manufacturing, labeling, advertising, marketing and distribution, and market surveillance of BD&#146;s medical products. The scope
of the activities of these agencies, particularly in the Europe, Japan and Asia Pacific regions in which BD operates, has been increasing. </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Prior to marketing or selling most of its products, BD must secure approval from the FDA and counterpart non-U.S. regulatory agencies. Following the introduction of a product, these agencies
engage in periodic reviews of BD&#146;s manufacturing processes and product performance. These regulatory controls can affect the time and cost associated with the development, introduction and continued availability of new products. Where possible,
BD anticipates these factors in its product development and planning processes. </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">These agencies possess the authority to take various administrative and legal actions against BD, such as product recalls, product seizures and other civil and criminal sanctions. BD also
undertakes voluntary compliance actions such as voluntary recalls. </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">In November 2006, we received a warning letter from the FDA resulting from an inspection of our facility in San Lorenzo, Puerto Rico, at which we manufacture certain blood collection products.
In response to the warning letter, BD developed and implemented a comprehensive corrective and preventive action plan that was reviewed by the FDA during a re-inspection of the San Lorenzo facility that was completed in fiscal year 2007. The FDA
found all warning letter commitments met and satisfactory and closed out the warning letter in fiscal year 2008. </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD believes it is in compliance in all material respects with the regulations promulgated by such agencies, and that such compliance has not had, and, BD believes, should not have, a material
adverse effect on BD. BD also believes that its operations comply in all material respects with applicable environmental laws and regulations. BD believes that our regulatory and environmental compliance has not had, and, will not have, a material
adverse effect on our operations or results. See Item 3. Legal Proceedings. </FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Employees</FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">As of September 30, 2008, BD had 28,277 employees, of whom 12,649 were employed in the United States (including Puerto Rico). BD believes that its employee relations are satisfactory.
</FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Other Matters</FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Becton Dickinson France, S.A. (&#147;BD-France&#148;), a subsidiary of BD, was listed among approximately 2,200 other companies in an October 27, 2005 report of the Independent Inquiry
Committee (&#147;IIC&#148;) of the United Nations (&#147;UN&#148;) as having been involved in humanitarian contracts in which unauthorized payments were suspected of having been made to the Iraqi Government in connection with the UN&#146;s
Oil-for-Food Programme (the &#147;Programme&#148;).  In connection with the IIC&#146;s report, Becton Dickinson AG, a Swiss subsidiary of BD, received a letter of inquiry from the Vendor Review Committee (&#147;VRC&#148;) of the United Nations
Procurement Service dated November 22, 2005. The letter of inquiry said that the VRC is reviewing Becton Dickinson AG&#146;s registration status in light of BD-France being listed in the IIC&#146;s report and asked us for any information we might
provide relating to the findings of the report. BD conducted an internal review and found no evidence that BD or any BD employee made, authorized, or approved improper payments to the Iraqi Government in connection with the Programme.  The
representative utilized by BD in Iraq also unequivocally denied having made any such payments, and BD was unable to find any evidence of such payments being made by this representative. BD has also reported the results of its internal review to the
VRC. In May 2008, BD received a letter from the U.N. stating that Becton, Dickinson AG has been suspended from the U.N. Secretariat Procurement Division&#146;s vendor roster for a minimum period of six months.  BD has sought review of the
suspension.  BD believes that the suspension has not had or will not have a material adverse effect on BD.</FONT></P>
<P align="center">
<FONT face="serif">5 </FONT><FONT size=1 face="serif"></FONT></P>

<HR noshade align="center" width="100%" size=4>



<P align="left" style="page-break-before:always"></P><PAGE>
<A name="page_6"></A>

<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">In May 2007, the French Judicial Police conducted searches of BD-France&#146;s offices in France with respect to the matters that were the subject of the 2005 IIC report. We were informed that
it is one of a number of companies named in the IIC report that is being investigated by the French Judicial Police. We are cooperating fully with the investigation. </FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Available Information</FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD maintains a website at </FONT><I><U><FONT size=2 face="serif">www.bd.com</FONT></U></I><I><FONT size=2 face="serif">.</FONT></I><FONT size=2 face="serif"> BD makes available its Annual
Reports on Form 10-K, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K (and amendments to those reports) as soon as reasonably practicable after those reports are electronically filed with or furnished to the Securities and
Exchange Commission (&#147;SEC&#148;). These filings may be found at </FONT><I><U><FONT size=2 face="serif">www.bd.com/investors</FONT></U></I><FONT size=2 face="serif">. Printed copies of the foregoing documents may also be obtained, without
charge, by contacting: Investor Relations, Becton, Dickinson and Company, 1 Becton Drive, Franklin Lakes, New Jersey 07417-1880, phone: 1-800-284-6845. </FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Forward-Looking Statements</FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD and its representatives may from time-to-time make certain forward-looking statements in publicly-released materials, both written and oral, including statements contained in this report and
filings with the SEC and in our other reports to shareholders. Additional information regarding our forward-looking statements is contained in the &#147;Financial Review&#148; contained in Exhibit 13. </FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Item 1A. </FONT></B><B><I><FONT size=2 face="serif">Risk Factors.</FONT></I></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">An investment in BD involves a variety of risks and uncertainties. The following describes some of the significant risks that could adversely affect BD&#146;s business, financial condition,
operating results or cash flows.</FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Current economic conditions could adversely affect our operations. </FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Financial markets in the United States and abroad have experienced extreme disruption, including severely diminished liquidity and credit availability. While these conditions and the current
economic downturn have not impaired our ability to access credit markets or adversely affected our operations to date, there can be no assurance that these conditions will not adversely affect our business in the future, particularly if there is
further deterioration in the world financial markets and major economies.  The current conditions may also adversely affect the business of our customers and the amount spent on healthcare generally. This could result in a decrease in the demand for
our products and services, longer sales cycles, slower adoption of new technologies and increased price competition.  In addition, these conditions may adversely affect our suppliers, such as resin suppliers that do substantial business with the
automotive industry, which could cause disruptions in our ability to produce our products. </FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Inflation could adversely affect the results of our operations.</FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our results of operations could be negatively impacted by inflation in the cost of raw materials, components, freight and energy. In particular, BD purchases supplies of resins, which are
oil-based components used in the manufacture of certain products. Any significant increases in resin purchase costs could impact future operating results. Increases in the price of oil can also increase BD&#146;s costs for packaging and
transportation. If we are unable to mitigate these cost increases, our profitability may be adversely affected. </FONT></P>
<P align="left">
<B><FONT size=2 face="serif">We are subject to foreign currency exchange risk.</FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Over half of our fiscal year 2008 revenues were derived from international operations. Our revenues outside the U.S. may be adversely affected by fluctuations in foreign currency exchange
rates.  Recently, worldwide currencies have experienced extreme volatility. A discussion of the financial impact of exchange rate fluctuations and the ways and extent to which we attempt to mitigate such impact is contained under the heading
&#147;Financial Instrument Market Risk&#148; under &#147;Financial Review&#148; contained in Exhibit 13, which is incorporated herein by reference.  We cannot predict with any certainty changes in foreign currency exchange rates or the degree to
which we can mitigate these risks. </FONT></P>
<P align="center">
<FONT face="serif">6 </FONT><FONT size=1 face="serif"></FONT></P>

<HR noshade align="center" width="100%" size=4>



<P align="left" style="page-break-before:always"></P><PAGE>
<A name="page_7"></A>

<P align="left">
<B><FONT size=2 face="serif">BD&#146;s future growth is dependent upon the development of new products, and there can be no assurance that such products will be developed.</FONT></B><FONT size=2 face="serif"> </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">A significant element of our strategy is to increase revenue growth by focusing on products that deliver greater benefits to patients, healthcare workers and researchers.  The development of
these products requires significant research and development, clinical trials and regulatory approvals.  The results of our product development efforts may be affected by a number of factors, including BD&#146;s ability to innovate, develop and
manufacture new products, complete clinical trials, obtain regulatory approvals and reimbursement in the United States and abroad, or gain and maintain market approval of our products. In addition, patents attained by others can preclude or delay
our commercialization of a product. There can be no assurance that any products now in development or that we may seek to develop in the future will achieve technological feasibility, obtain regulatory approval, or gain market acceptance.
</FONT></P>
<P align="left">
<B><FONT size=2 face="serif">The medical device industry is very competitive.</FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The medical device industry is subject to rapid technological changes, and we face significant competition across our product lines and in each market in which our products are sold. We face
this competition from a wide range of companies. These include large medical device companies, some of which may have greater financial and marketing resources than us. We also face competition from firms that are more specialized than us with
respect to particular markets. Non-medical device companies, including pharmaceutical companies, also offer or are attempting to develop alternative therapies for disease states that may be delivered without a medical device. See
&#147;Competition&#148; under Item 1.  Business.  The development of new or improved products, processes or technologies by other companies (such as needle-free injection technology) may render our products or proposed products obsolete or less
competitive. In addition, the entry into the market of manufacturers located in China and other low-cost manufacturing locations are creating increased pricing pressures, particularly in developing markets. Some competitors have also established
manufacturing sites or have contracted with suppliers located in these countries as a means to lower their costs. New entrants may also appear, particularly from these low-cost countries. </FONT></P>
<P align="left">
<B><FONT size=2 face="serif">A reduction or interruption in the supply of certain raw materials and components would adversely affect BD&#146;s manufacturing operations and related product sales.</FONT></B><FONT size=2 face="serif"> </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD purchases many different types of raw materials and components. We have generally been able to obtain adequate supplies of these materials. However, certain raw materials (primarily related
to the BD Biosciences segment) and components are not available from multiple sources.  In addition, for quality assurance, cost-effectiveness and other reasons, BD elects to purchase certain raw materials and components from sole suppliers. The
supply of these materials can be disrupted for a number of reasons. While we work with suppliers to ensure continuity of supply, no assurance can be given that these efforts will be successful. In addition, where there are regulatory requirements
relating to the qualification of suppliers, we may not be able to establish additional or replacement sources on a timely basis. The termination, reduction or interruption in supply of these sole-sourced raw materials and components could impact our
ability to manufacture and sell certain of our products.</FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Interruption of our manufacturing operations could adversely affect BD&#146;s future revenues and operating income.</FONT></B><FONT size=2 face="serif"> </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">We have manufacturing sites all over the world. In addition, in some instances, the manufacturing of certain of our product lines is concentrated in one or more of our plants. As a result,
weather, natural disasters (including pandemic disease), terrorism, political change, or damage to one or more of our facilities could adversely affect our ability to manufacture our products. </FONT></P>
<P align="left">
<B><FONT size=2 face="serif">BD is subject to a number of pending lawsuits</FONT></B><FONT size=2 face="serif">.</FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD is a defendant in a number of pending lawsuits, including purported class action lawsuits for alleged antitrust violations and product liability, and could be subject to additional lawsuits
in the future. A more detailed description of these lawsuits is contained in Item 3. Legal Proceedings. Given the uncertain nature of litigation generally, we are not able in all cases to estimate the amount or range of loss that could result from
an unfavorable</FONT></P>
<P align="center">
<FONT face="serif">7 </FONT><FONT size=1 face="serif"></FONT></P>

<HR noshade align="center" width="100%" size=4>



<P align="left" style="page-break-before:always"></P><PAGE>
<A name="page_8"></A>

<P align="left">
<FONT size=2 face="serif">outcome of the litigation to which we are a party. In view of these uncertainties, we could incur charges in excess of any currently established accruals and, to the extent available, excess liability insurance.  Any such
future charges, individually or in the aggregate, could adversely effect BD&#146;s results of operations and cash flows. </FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Consolidation in the healthcare industry could adversely affect BD&#146;s future revenues and operating income.</FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The medical device industry has experienced a significant amount of consolidation.  As a result of this consolidation, competition to provide goods and services to customers has increased.  In
addition, group purchasing organizations and integrated health delivery networks have served to concentrate purchasing decisions for some customers, which has placed pricing pressure on medical device suppliers. Further consolidation in the industry
could exert additional pressure on the prices of our products.</FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Changes in reimbursement practices of third-party payers could affect the demand for our products and the prices at which they are sold.</FONT></B><FONT size=2 face="serif"> </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our sales depend, in part, on the extent to which healthcare providers and facilities are reimbursed by government authorities, private insurers and other third-party payers for the costs of
our products. The coverage policies and reimbursement levels of third-party payers may affect which products customers purchase and the prices they are willing to pay for these products. Legislative or administrative reforms to reimbursement systems
in the U.S. or abroad could significantly reduce reimbursement for procedures using BD medical devices, or result in denial of reimbursement for those products. See &#147;Third-Party Reimbursement&#148; under Item 1. Business.</FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Product defects could adversely affect the results of our operations.</FONT></B><FONT size=2 face="serif"> </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The design, manufacture and marketing of medical devices involve certain inherent risks. Manufacturing or design defects, unanticipated use of our products, or inadequate disclosure of risks
relating to the use of the product can lead to injury or other adverse events. These events could lead to recalls or safety alerts relating to our products (either voluntary or required by the FDA or similar governmental authorities in other
countries), and could result, in certain cases, in the removal of a product from the market. Any recall could result in significant costs, as well as negative publicity and damage to our reputation that could reduce demand for our products. Personal
injuries relating to the use of our products can also result in product liability claims being brought against us. In some circumstances, such adverse events could also cause delays in new product approvals. </FONT></P>
<P align="left">
<B><FONT size=2 face="serif">We may experience difficulties implementing our enterprise resource planning system. </FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">We have initiated a project to upgrade our enterprise resource planning (&#147;ERP&#148;) system. Our ERP system is critical to our ability to accurately maintain books and records, record
transactions, provide important information to our management and prepare our financial statements. The design and implementation of the new ERP system will require the investment of significant financial and human resources. The total cost needed
to implement the new ERP system may turn out to be more than we currently anticipate.  In addition, we may not be able to successfully implement the new ERP system without experiencing difficulties.  Any disruptions, delays or deficiencies in the
design and implementation of the new ERP system could adversely affect our ability to process orders, ship products, provide services and customer support, send invoices and track payments, fulfill contractual obligations or otherwise operate our
business, which could, in turn, adversely affect our results of operations, financial condition and cash flows.</FONT></P>
<P align="left">
<B><FONT size=2 face="serif">BD is subject to extensive regulation.</FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD is subject to extensive regulation by the FDA pursuant to the Federal Food, Drug and Cosmetic Act, by comparable agencies in foreign countries, and by other regulatory agencies and governing
bodies. Most of BD&#146;s products must receive clearance or approval from the FDA or counterpart non-U.S. regulatory agencies before they can be marketed or sold. The process for obtaining marketing approval or clearance may take a significant
period of time and require the expenditure of substantial resources. The process may also require changes to our products or result in limitations on the indicated uses of the products. In addition, regulatory requirements outside the U.S. change
frequently, requiring prompt action to maintain compliance, particularly when product modifications are required.</FONT></P>
<P align="center">
<FONT face="serif">8 </FONT><FONT size=1 face="serif"></FONT></P>

<HR noshade align="center" width="100%" size=4>



<P align="left" style="page-break-before:always"></P><PAGE>
<A name="page_9"></A>

<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Following the introduction of a product, these agencies also periodically review our manufacturing processes and product performance. Our failure to comply with the applicable good
manufacturing practices, adverse event reporting, clinical trial and other requirements of these agencies could delay or prevent the production, marketing or sale of our products and result in fines, delays or suspensions of regulatory clearances,
closure of manufacturing sites, seizures or recalls of products and damage to our reputation.</FONT></P>
<P align="left">
<B><FONT size=2 face="serif">We cannot guarantee that any of BD&#146;s strategic acquisitions, investments or alliances will be successful.</FONT></B><FONT size=2 face="serif"> </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">While our strategy to increase revenue growth is driven primarily by internal product development, we will seek to supplement our growth through strategic acquisitions, investments and
alliances. Such transactions are inherently risky. The success of any acquisition, investment or alliance may be affected by a number of factors, including our ability to properly assess and value the potential business opportunity or to
successfully integrate it into our existing business. There can be no assurance that any past or future transaction will be successful.</FONT></P>
<P align="left">
<B><FONT size=2 face="serif">The international operations of BD&#146;s business may subject BD to certain business risks.</FONT></B><FONT size=2 face="serif"> </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD operations outside the U.S. subject BD to certain risks, including the effects of fluctuations in foreign currency exchange (as discussed above), the spread of a global economic downturn,
changes in foreign regulatory requirements, potential political instability, trade barriers, weakening of the protection of intellectual property rights in some countries, and restrictions on the transfer of capital across borders. The success of
our operations outside the U.S. will depend, in part, on our ability to acquire or form alliances with local companies and make necessary infrastructure enhancements to, among other things, our production facilities and distribution networks.
</FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Reductions in customers&#146; research budgets or government funding may adversely affect our BD Biosciences segment.</FONT></B><FONT size=2 face="serif"> </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our BD Biosciences segment sells products to researchers at pharmaceutical and biotechnology companies, academic institutions, government laboratories and private foundations. Research and
development spending of our customers can fluctuate based on spending priorities and general economic conditions. A number of these customers are also dependent upon grants from U.S. government agencies, such as the U.S. National Institutes of
Health (&#147;NIH&#148;), and agencies in other countries for their funding. The level of government funding of research and development is unpredictable, and may be adversely affected by the current economic downturn. In addition, there have been
instances where NIH grants have been frozen or otherwise unavailable for extended periods. Any reduction or delay in governmental funding could cause our customers to delay or forego purchases of our products.</FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Our operations are dependent in part on patents and other intellectual property rights.</FONT></B><FONT size=2 face="serif"> </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Many of BD&#146;s businesses rely on patent, trademark and other intellectual property rights. While we do not believe that the loss of any one patent or other intellectual property asset would
materially adversely affect BD operations, these intellectual property assets, in the aggregate, are of material importance to our business. BD can lose the protection afforded by these intellectual property assets through patent expirations, legal
challenges or governmental action. Patents attained by competitors, particularly as patents on our products expire, may also adversely affect our competitive position. The loss of a significant portion of our portfolio of intellectual property
assets may have an adverse effect on our earnings, financial condition or cash flows.</FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Natural disasters, war and other events could adversely affect BD&#146;s future revenues and operating income.</FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Natural disasters, pandemics, war, terrorism, labor disruptions and international conflicts, and actions taken by the United States and other governments in response to such events, could cause
significant economic disruption and political and social instability in the U.S. and in areas outside of the U.S. in which we operate. These events could result in decreased demand for our products, adversely affect our manufacturing and
distribution capabilities, or increase the costs for or cause interruptions in the supply of materials from our suppliers. </FONT></P>
<P align="center">
<FONT face="serif">9 </FONT><FONT size=1 face="serif"></FONT></P>

<HR noshade align="center" width="100%" size=4>



<P align="left" style="page-break-before:always"></P><PAGE>
<A name="page_10"></A>

<P align="left">
<B><FONT size=2 face="serif">We need to attract and retain key employees to be competitive. </FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Our ability to compete effectively depends upon our ability to attract and retain executives and other key employees, including people in technical, marketing, sales and research positions.
Competition for experienced employees, particularly for persons with specialized skills, can be intense. The Company&#146;s ability to recruit such talent will depend on a number of factors, including compensation and benefits, work location and
work environment. If we cannot effectively recruit and retain qualified executives and employees, our business could be adversely affected.</FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Item 1B. </FONT></B><B><I><FONT size=2 face="serif">Unresolved Staff Comments.</FONT></I></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">None.</FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Item 2. </FONT></B><B><I><FONT size=2 face="serif">Properties.</FONT></I></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD&#146;s executive offices are located in Franklin Lakes, New Jersey. As of November 1, 2008, BD owned and leased approximately 16,061,566  square feet of manufacturing, warehousing,
administrative and research facilities throughout the world. The U.S. facilities, including Puerto Rico, comprise approximately 6,813,412 square feet of owned and 1,858,102 square feet of leased space. The international facilities comprise
approximately 5,940,130 square feet of owned and 1,449,922 square feet of leased space. Sales offices and distribution centers included in the total square footage are also located throughout the world. </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Operations in each of BD&#146;s business segments are conducted at both U.S. and international locations. Particularly in the international marketplace, facilities often serve more than one
business segment and are used for multiple purposes, such as administrative/sales, manufacturing and/or warehousing/distribution. BD generally seeks to own its manufacturing facilities, although some are leased.</FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD believes that its facilities are of good construction and in good physical condition, are suitable and adequate for the operations conducted at those facilities, and are, with minor
exceptions, fully utilized and operating at normal capacity. </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The U.S. facilities include facilities in Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Maryland, Massachusetts, Michigan, Missouri, Nebraska, New Jersey, North
Carolina, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Washington, DC, Washington, Wisconsin and Puerto Rico. </FONT></P>
<P align="left">
<FONT size=2 face="serif">The international facilities are grouped as follows:</FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">&#151;Canada includes approximately 65,650 square feet of owned and 152,891 square feet of leased space. </FONT></P>
<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">&#151;Europe and Eastern Europe, Middle East and Africa include facilities in Austria,
  Belgium, Denmark, Egypt, England, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Kenya, the Netherlands, Norway, Poland, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey and the United Arab Emirates, and are
  comprised of approximately 2,686,331 square feet of owned and 692,642 square feet of leased space. </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">&#151;Latin America includes facilities in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, Peru and Venezuela, and is comprised of approximately 1,385,454 square feet of owned and
253,054 square feet of leased space. </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">&#151;Asia Pacific includes facilities in Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Pakistan, the Philippines, Singapore, South Korea, Taiwan, Thailand and
Vietnam, and is comprised of approximately 1,802,695 square feet of owned and 351,335 square feet of leased space. </FONT></P>
<P align="center">
<FONT face="serif">10 </FONT><FONT size=1 face="serif"></FONT></P>

<HR noshade align="center" width="100%" size=4>



<P align="left" style="page-break-before:always"></P><PAGE>
<p><A name="page_11"></A></p>
<p> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The following table summarizes property information
by business segment. </FONT></p>
<TABLE border=0 width=100% cellspacing=0 cellpadding=0>
<TR valign="bottom">
	<TD align=left width=22% nowrap style="border-bottom:1px solid #000000;">&nbsp;	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=9% nowrap style="border-bottom:1px solid #000000;">
      <div align="center"><B><FONT size=2 face="serif">Corporate</FONT></B>      </div></TD>
	<TD width=2%>
	  </TD>
	<TD align=right width=11% nowrap style="border-bottom:1px solid #000000;">
      <div align="center"><B><FONT size=2 face="serif">Biosciences</FONT></B>      </div></TD>
	<TD width=2%>
	  </TD>
	<TD align=right width=10% nowrap style="border-bottom:1px solid #000000;">
      <div align="center"><B><FONT size=2 face="serif">Medical</FONT></B>      </div></TD>
	<TD width=2%>
	  </TD>
	<TD align=right width=11% nowrap style="border-bottom:1px solid #000000;">
      <div align="center"><B><FONT size=2 face="serif">Diagnostics</FONT></B>      </div></TD>
	<TD width=2%>
	  </TD>
	<TD align=right width=11% nowrap style="border-bottom:1px solid #000000;">
      <div align="center"><B><FONT size=2 face="serif">Mixed (A)</FONT></B>      </div></TD>
	<TD width=2%>
	  </TD>
	<TD align=right width=9% nowrap style="border-bottom:1px solid #000000;">
      <div align="center"><B><FONT size=2 face="serif">Total</FONT></B>      </div></TD>
</TR>
<TR valign="bottom">
	<TD align=left width=22% nowrap>
<FONT  size=2 face="serif">Leased</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=left width=9% nowrap>&nbsp;	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=left width=11% nowrap>&nbsp;	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>&nbsp;	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=left width=11% nowrap>&nbsp;	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=left width=11% nowrap>&nbsp;	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=left width=9% nowrap>&nbsp;	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=22% nowrap>
 &nbsp; &nbsp;<FONT  size=2 face="serif">Sites</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=9% nowrap>
<FONT  size=2 face="serif">2</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">11</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=10% nowrap>
<FONT  size=2 face="serif">70</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">12</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">35</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=9% nowrap>
<FONT  size=2 face="serif">130</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=22% nowrap>
 &nbsp; &nbsp;<FONT  size=2 face="serif">Square feet</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=9% nowrap>
<FONT  size=2 face="serif">5,112</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">315,648</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=10% nowrap>
<FONT  size=2 face="serif">1,245,104</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">227,271</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">1,514,889</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=9% nowrap>
<FONT  size=2 face="serif">3,308,024</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=22% nowrap>
 &nbsp; &nbsp;<FONT  size=2 face="serif">Manufacturing square footage</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=9% nowrap>
<FONT  size=2 face="serif">0</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">29,914</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=10% nowrap>
<FONT  size=2 face="serif">291,353</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">46,213</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">0</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=9% nowrap>
<FONT  size=2 face="serif">367,480</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=22% nowrap>
 &nbsp; &nbsp;<FONT  size=2 face="serif">Manufacturing sites</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=9% nowrap>
<FONT  size=2 face="serif">0</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">3</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=10% nowrap>
<FONT  size=2 face="serif">7</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">3</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">0</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=9% nowrap>
<FONT  size=2 face="serif">13</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=22% nowrap>
<FONT  size=2 face="serif">Owned</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=left width=9% nowrap>&nbsp;	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=left width=11% nowrap>&nbsp;	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>&nbsp;	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=left width=11% nowrap>&nbsp;	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=left width=11% nowrap>&nbsp;	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=left width=9% nowrap>&nbsp;	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=22% nowrap>
 &nbsp; &nbsp;<FONT  size=2 face="serif">Sites</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=9% nowrap>
<FONT  size=2 face="serif">2</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">6</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=10% nowrap>
<FONT  size=2 face="serif">24</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">13</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">9</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=9% nowrap>
<FONT  size=2 face="serif">54</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=22% nowrap>
 &nbsp; &nbsp;<FONT  size=2 face="serif">Square feet</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=9% nowrap>
<FONT  size=2 face="serif">489,094</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">831,330</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=10% nowrap>
<FONT  size=2 face="serif">6,210,561</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">2,519,385</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">2,703,172</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=9% nowrap>
<FONT  size=2 face="serif">12,753,542</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=22% nowrap>
 &nbsp; &nbsp;<FONT  size=2 face="serif">Manufacturing square footage</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=9% nowrap>
<FONT  size=2 face="serif">0</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">395,330</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=10% nowrap>
<FONT  size=2 face="serif">3,988,933</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">1,456,561</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">300,550</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=9% nowrap>
<FONT  size=2 face="serif">6,141,374</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=22% nowrap>
 &nbsp; &nbsp;<FONT  size=2 face="serif">Manufacturing sites</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=9% nowrap>
<FONT  size=2 face="serif">0</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">6</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=10% nowrap>
<FONT  size=2 face="serif">24</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">13</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">2</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=9% nowrap>
<FONT  size=2 face="serif">45</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=22% nowrap>
<FONT  size=2 face="serif">Total</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=left width=9% nowrap>&nbsp;	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=left width=11% nowrap>&nbsp;	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>&nbsp;	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=left width=11% nowrap>&nbsp;	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=left width=11% nowrap>&nbsp;	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=left width=9% nowrap>&nbsp;	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=22% nowrap>
 &nbsp; &nbsp;<FONT  size=2 face="serif">Sites</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=9% nowrap>
<FONT  size=2 face="serif">4</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">17</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=10% nowrap>
<FONT  size=2 face="serif">94</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">25</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">44</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=9% nowrap>
<FONT  size=2 face="serif">184</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=22% nowrap>
 &nbsp; &nbsp;<FONT  size=2 face="serif">Square feet</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=9% nowrap>
<FONT  size=2 face="serif">494,206</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">1,146,978</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=10% nowrap>
<FONT  size=2 face="serif">7,455,665</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">2,746,656</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">4,218,061</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=9% nowrap>
<FONT  size=2 face="serif">16,061,566</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=22% nowrap style="border-bottom:0px solid #000000;">
 &nbsp; &nbsp;<FONT  size=2 face="serif">Manufacturing square footage</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=9% nowrap style="border-bottom:0px solid #000000;">
<FONT  size=2 face="serif">0</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap style="border-bottom:0px solid #000000;">
<FONT  size=2 face="serif">425,244</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=10% nowrap style="border-bottom:0px solid #000000;">
<FONT  size=2 face="serif">4,280,286</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap style="border-bottom:0px solid #000000;">
<FONT  size=2 face="serif">1,502,774</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap style="border-bottom:0px solid #000000;">
<FONT  size=2 face="serif">300,550</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=9% nowrap style="border-bottom:0px solid #000000;">
<FONT  size=2 face="serif">6,508,854</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=22% nowrap>
 &nbsp; &nbsp;<FONT  size=2 face="serif">Manufacturing sites</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=9% nowrap>
<FONT  size=2 face="serif">0</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">9</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=10% nowrap>
<FONT  size=2 face="serif">31</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">16</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=11% nowrap>
<FONT  size=2 face="serif">2</FONT>	</TD>
	<TD width=2%>&nbsp;	</TD>
	<TD align=right width=9% nowrap>
<FONT  size=2 face="serif">58</FONT>	</TD>
</TR>
</TABLE>
<BR>
<P align="left"> <FONT  size=2 face="serif">(A) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Facilities used by all business
segments. </FONT></P>
<P align="left"><B><FONT  size=2 face="serif">Item 3. </FONT></B><B><I><FONT  size=2 face="serif">Legal Proceedings.</FONT></I></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT  size=2 face="serif">BD is named as a defendant
in five purported class action suits brought on behalf of direct purchasers of
BD&#146;s products, such as distributors, alleging that BD violated
federal antitrust laws, resulting in the charging of higher prices for BD&#146;s
products to the plaintiff and other purported class members. The cases filed
are as follows:</FONT> <I><FONT  size=2 face="serif">Louisiana Wholesale Drug
Company, Inc., et. al. vs. Becton Dickinson and Company </FONT></I><FONT  size=2 face="serif">(Civil
Action No. 05-1602, U.S. District Court, Newark, New Jersey),  filed on March
25, 2005; </FONT><I><FONT  size=2 face="serif">SAJ Distributors,
Inc. et. al. vs. Becton Dickinson &amp; Co. </FONT></I><FONT  size=2 face="serif">(Case
2:05-CV-04763-JD, U.S. District Court, Eastern  District of Pennsylvania), filed
on September 6, 2005; </FONT><I><FONT  size=2 face="serif">Dik Drug Company,
et. al. vs. Becton, Dickinson and Company</FONT></I><FONT  size=2 face="serif"> (Case
No. 2:05-CV-04465, U.S.  District Court, Newark, New Jersey), filed on September
12, 2005; </FONT><I><FONT  size=2 face="serif">American
Sales Company, Inc. et. al. vs. Becton, Dickinson &amp; Co.</FONT></I><FONT  size=2 face="serif"> (Case
No.  2:05-CV-05212-CRM, U.S. District Court, Eastern District of Pennsylvania),
filed on October 3, 2005; and </FONT><I><FONT  size=2 face="serif">Park Surgical
Co. Inc. et. al. vs. Becton, Dickinson and Company</FONT></I><FONT  size=2 face="serif"> (Case
2:05-CV-05678-CMR, U.S. District Court, Eastern District of Pennsylvania), filed
on October 26, 2005.</FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT  size=2 face="serif">The actions brought by Louisiana Wholesale Drug Company and Dik Drug Company in New Jersey have been consolidated under the caption &#147;</FONT><I><FONT  size=2 face="serif">In re Hypodermic Products Antitrust Litigation</FONT></I><FONT  size=2 face="serif">.&#148;</FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT  size=2 face="serif">BD is also named as
a defendant in four purported class action suits brought on behalf of indirect
purchasers of BD&#146;s products, alleging that BD violated federal antitrust
 laws, resulting in the charging of higher prices for BD&#146;s products to the
 plaintiff and other purported class members. The cases filed are as follows:  </FONT><I><FONT  size=2 face="serif">Jabo&#146;s
 Pharmacy, Inc., et. al. v.  Becton Dickinson &amp; Company</FONT></I><FONT  size=2 face="serif"> (Case
 No. 2:05-CV-00162, U.S. District Court, Greenville, Tennessee), filed on June
 7, 2005;</FONT><I><FONT  size=2 face="serif"> Drug Mart Tallman,
Inc., et. al. v. Becton Dickinson and Company</FONT></I> <FONT  size=2 face="serif">(Case
No. 2:06-CV-00174, U.S. District Court, Newark, New Jersey), filed on January
17, 2006; <I>Medstar v. Becton Dickinson</I> (Case
No. 06-CV-03258-JLL (RJH), U.S. District Court, Newark, New Jersey), filed on
May 18, 2006; and <I>The Hebrew Home for the
Aged at Riverdale v. Becton Dickinson and  Company</I> (Case
No. 07-CV-2544, U.S. District Court, Southern District of New York), filed on
March 28, 2007. A fifth purported class action on behalf of indirect purchasers
(<I>International
Multiple Sclerosis Management Practice v. Becton Dickinson &amp; Company</I> (Case
No. 2:07-cv-10602, U.S. District Court, Newark, New Jersey), filed  on April
5, 2007) was voluntarily withdrawn by the plaintiff. </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT  size=2 face="serif">The plaintiffs in each of the antitrust class action lawsuits seek monetary damages. All of the antitrust class action lawsuits have been consolidated for pre-trial purposes in
a Multi-District Litigation (MDL) in federal court in New Jersey.</FONT></P>
<P align="center">
<FONT face="serif">11 </FONT><FONT size=1 face="serif"></FONT></P>
<P align="left">&nbsp;</P>
<HR noshade align="center" width="100%" size=4>



<P align="left" style="page-break-before:always"></P><PAGE>
<A name="page_12"></A>

<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">On June 6, 2006, UltiMed, Inc., a Minnesota company, filed suit against BD in the U.S. District Court in Minneapolis, Minnesota (</FONT><I><FONT size=2 face="serif">UltiMed, Inc. v. Becton,
Dickinson and Company</FONT></I><FONT size=2 face="serif"> (06CV2266)). The plaintiff alleges, among other things, that BD excluded the plaintiff from the market for home use insulin syringes by entering into anticompetitive contracts in violation
of federal and state antitrust laws. The plaintiff seeks money damages and injunctive relief. </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">In June 2007, Retractable Technologies, Inc. (&#147;RTI&#148;)
filed a complaint against BD under the caption</FONT> <I><FONT size=2 face="serif">Retractable
Technologies, Inc. vs. Becton Dickinson and Company </FONT></I><FONT size=2 face="serif">(Civil
Action No. 2:07-cv-250, U.S. District Court, Eastern District of Texas). RTI
alleges that the BD Integra&#153;
syringes infringe patents licensed exclusively to RTI. In its complaint, RTI
also alleges that BD engaged in false advertising with respect to certain of
BD&#146;s safety-engineered products in violation of the Lanham Act; acted to
exclude RTI from  various product markets and to maintain its market share through,
among other things, exclusionary contracts in violation of state and federal
antitrust laws; and engaged in unfair competition. In January 2008, the court
granted BD&#146;s motion to
sever the patent and non-patent claims into separate cases.  The non-patent claims
have been stayed, pending resolution of RTI&#146;s
patent claims. The trial on the patent claims is currently scheduled to commence
in March 2009. RTI seeks money damages and injunctive relief. On April 1, 2008,
RTI filed a complaint against BD under the caption </FONT><I><FONT size=2 face="serif">Retractable
Technologies, Inc. and Thomas J. Shaw v. Becton Dickinson and Company</FONT></I><FONT size=2 face="serif"> (Civil
Action No. 2:08-cv-141, U.S. District Court, Eastern District of Texas). RTI
alleges that the BD Integra&#153; syringes infringe another patent licensed exclusively
to RTI. RTI seeks money damages and injunctive relief. On August 29, 2008, the
court ordered the consolidation of these two cases. </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD, along with another manufacturer and several medical product distributors, is named as a defendant in two product liability lawsuits relating to healthcare workers who allegedly sustained
accidental needlesticks, but have not become infected with any disease.  Generally, these actions allege that healthcare workers have sustained needlesticks using hollow-bore needle devices manufactured by BD and, as a result, require medical
testing, counseling and/or treatment. In some cases, these actions additionally allege that the healthcare workers have sustained mental anguish. Plaintiffs seek money damages in all of these actions. BD had previously been named as a defendant in
nine similar suits relating to healthcare workers who allegedly sustained accidental needlesticks, each of which has either been dismissed with prejudice or voluntarily withdrawn. Regarding the two pending suits: </FONT></P>
<UL>
<LI>
<P align="left"><FONT size=2 face="serif">In Ohio, </FONT><I><FONT size=2 face="serif">Grant vs. Becton Dickinson et al</FONT></I><FONT size=2 face="serif">. (Case No. 98CVB075616, Franklin County Court), on</FONT> <FONT size=2 face="serif">September 21, 2006, the Ohio Court of Appeals reversed the trial court&#146;s grant of class certification. The</FONT> <FONT size=2 face="serif">matter has been remanded to the trial court for a determination of whether the class can be
redefined.</FONT></P></LI>
<LI>
<P align="left"><FONT size=2 face="serif">In South Carolina, a suit has been filed on behalf of an unspecified number of healthcare workers seeking</FONT> <FONT size=2 face="serif">class action certification in state court under the caption
</FONT><I><FONT size=2 face="serif">Bales vs. Becton Dickinson et. al. </FONT></I><FONT size=2 face="serif">(Case No. 98-CP-</FONT><FONT size=2 face="serif">40-4343, Richland County Court of Common Pleas), filed on November 25,
1998.</FONT></P>
</LI>
</UL>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD continues to oppose class action certification in the pending cases, including pursuing all appropriate rights of appeal. </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD, along with a number of other manufacturers, was named as a defendant in approximately 524 product liability lawsuits in various state and Federal courts related to natural rubber latex
gloves which BD ceased manufacturing in 1995. Cases pending in Federal court are being coordinated under the matter </FONT><I><FONT size=2 face="serif">In re Latex Gloves Products Liability Litigation</FONT></I><FONT size=2 face="serif"> (MDL Docket
No. 1148) in Philadelphia, and analogous procedures have been implemented in the state courts of California, Pennsylvania, New Jersey and New York. Generally, these actions allege that medical personnel have suffered allergic reactions ranging from
skin irritation to anaphylaxis as a result of exposure to medical gloves containing natural rubber latex. Since the inception of this litigation, 467 of these cases have been closed with no liability to BD, and 46 cases have been settled for an
aggregate de minimis amount. </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">On May 28, 2004, Therasense, Inc. (&#147;Therasense&#148;) filed suit against BD (</FONT><I><FONT size=2 face="serif">Therasense, Inc. and Abbott Laboratories v. Nova Biomedical Corporation and
Becton, Dickinson and Company </FONT></I><FONT size=2 face="serif">(Case Number: C 04-02123 WDA, U.S. District Court, Northern District of California)) asserting that BD&#146;s blood glucose monitoring products infringe four Therasense patents and
seeking money damages. On August 10, 2004, in response to a motion filed by Therasense in the U.S. District Court for the District of Massachusetts, the court transferred to the</FONT></P>
<P align="center">
<FONT face="serif">12 </FONT><FONT size=1 face="serif"></FONT></P>

<HR noshade align="center" width="100%" size=4>



<P align="left" style="page-break-before:always"></P><PAGE>
<A name="page_13"></A>

<P align="left">
<FONT size=2 face="serif">court in California an action previously filed by BD against Therasense requesting a declaratory judgment that BD&#146;s products do not infringe the Therasense patents and that the Therasense patents are invalid. On April
4, 2008, the Court granted BD summary judgment with respect to two of the patents asserted against BD, finding no infringement by BD. On June 24, 2008, the Court ruled that a third patent asserted against BD was invalid and unenforceable.  On August
8, 2008, a jury delivered a verdict in BD&#146;s favor, finding that the last of the four patents asserted against BD was invalid.  Abbott/Therasense have appealed some of these decisions, and it is possible that other decisions will also be
appealed after the Court rules on post-trial motions. </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">On September 19, 2007, BD was served with a qui tam complaint filed by a private party against BD in the United States District Court, Northern District of Texas, alleging violations of the
Federal False Claims Act (&#147;FCA&#148;) and the Texas False Claims Act (the &#147;TFCA&#148;) (</FONT><I><FONT size=2 face="serif">U.S. ex rel Fitzgerald v. BD et al. </FONT></I><FONT size=2 face="serif">(Civil Action No. 3:03-CV-1589, U.S.
District Court, Northern District of Texas).  The suit alleges that a group purchasing organization&#146;s practices with its suppliers, including BD, inflated the costs of healthcare reimbursement. Under the FCA, the United States Department of
Justice, Civil Division has a certain period of time in which to decide whether to join the claim against BD as an additional plaintiff; if not, the private plaintiff is free to pursue the claim on its own. A similar process is followed under the
TFCA. To BD&#146;s knowledge, no decision has yet been made by the Civil Division or the State of Texas whether to join this claim.  In September 2008, the Court dismissed certain of the plaintiff&#146;s claims, but denied the Company&#146;s motion
to dismiss with respect to other claims.</FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD believes that it has meritorious defenses to each of the above-mentioned suits pending against BD and is engaged in a vigorous defense of each of these matters.</FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD is also involved both as a plaintiff and a defendant in other legal proceedings and claims that arise in the ordinary course of business. </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD is a party to a number of Federal proceedings in the United States brought under the Comprehensive Environment Response, Compensation and Liability Act, also known as &#147;Superfund,&#148;
and similar state laws. The affected sites are in varying stages of development. In some instances, the remedy has been completed, while in others, environmental studies are commencing. For all sites, there are other potentially responsible parties
that may be jointly or severally liable to pay all cleanup costs.</FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Given the uncertain nature of litigation generally, BD is not able in all cases to estimate the amount or range of loss that could result from an unfavorable outcome of the litigation to which
BD is a party. In accordance with U.S. generally accepted accounting principles, BD establishes accruals to the extent probable future losses are estimable (in the case of environmental matters, without considering possible third-party recoveries).
In view of the uncertainties discussed above, BD could incur charges in excess of any currently established accruals and, to the extent available, excess liability insurance.  In the opinion of management, any such future charges, individually or in
the aggregate, could have a material adverse effect on BD&#146;s consolidated results of operations and consolidated cash flows. </FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Item 4. </FONT></B><B><I><FONT size=2 face="serif">Submission of Matters to a Vote of Security Holders.</FONT></I></B><FONT size=2 face="serif"> </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">None.</FONT></P>
<P align="center">
<FONT face="serif">13 </FONT><FONT size=1 face="serif"></FONT></P>

<HR noshade align="center" width="100%" size=4>



<P align="left" style="page-break-before:always"></P><PAGE>
<A name="page_14"></A>

<P align="left">
<B><FONT size=2 face="serif">Executive Officers of the Registrant</FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The following is a list of the executive officers of BD, their ages and all positions and offices held by each of them during the past five years. There is no family relationship between any
executive officer or director of BD. </FONT></P>
<TABLE border=0 width=100% cellspacing=0 cellpadding=0>
<TR valign="bottom">
	<TD align=left width=20% nowrap style="border-bottom:1px solid #000000;">
<B><FONT size=2 face="serif">Name</FONT></B>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=10% nowrap style="border-bottom:1px solid #000000;">
      <div align="center"><B><FONT size=2 face="serif">Age</FONT></B>      </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=center width=60% nowrap style="border-bottom:1px solid #000000;">
<B><FONT size=2 face="serif">Position</FONT></B>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>
<FONT size=2 face="serif">Edward J. Ludwig</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=10% nowrap>
      <div align="center"><FONT size=2 face="serif">57</FONT>      </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">Director since 1999; Chairman, President and Chief Executive</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">Officer since February 2002.</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>
<FONT size=2 face="serif">Donna M. Boles</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=10% nowrap>
      <div align="center"><FONT size=2 face="serif">55</FONT>      </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">Senior Vice President&#151;Human Resources since June 2006; Vice</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">President&#151;Human Resources from June 2005 to June 2006;</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">and, prior thereto, Vice President, Human Resources, BD</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">Medical.</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>
<FONT size=2 face="serif">Scott P. Bruder</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=10% nowrap>
      <div align="center"><FONT size=2 face="serif">46</FONT>      </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">Senior Vice President and Chief Technology Officer since</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">September 2007; Worldwide Vice President, Johnson &amp; Johnson</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">Regenerative Therapeutics, LLC from December 2005 to August</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">2007; Worldwide Vice President, DePuy Biologics, a unit of</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">DePuy, Inc., a Johnson &amp; Johnson Company, from October 2003</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">to November 2005; and, prior thereto, Worldwide Vice</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">President, Orthobiologics, DePuy Spine, DePuy Orthopaedics,</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">and DePuy Mitek, operating companies within DePuy, Inc.</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>
<FONT size=2 face="serif">Gary M. Cohen</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=10% nowrap>
      <div align="center"><FONT size=2 face="serif">49</FONT>      </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">Executive Vice President since June 2006; and, prior thereto,</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">President&#151;BD Medical.</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>
<FONT size=2 face="serif">John R. Considine</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=10% nowrap>
      <div align="center"><FONT size=2 face="serif">58</FONT>      </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">Vice Chairman and Chief Financial Officer since March 2008;</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">Senior Executive Vice President and Chief Financial Officer</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">from June 2006 to March 2008; and, prior thereto, Executive</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">Vice President and Chief Financial Officer.</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>
<FONT size=2 face="serif">David T. Durack</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=10% nowrap>
      <div align="center"><FONT size=2 face="serif">63</FONT>      </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">Senior Vice President&#151;Corporate Medical Affairs since June</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">2006; and, prior thereto, Vice President&#151;Corporate Medical</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">Affairs.</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>
<FONT size=2 face="serif">Vincent A. Forlenza</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=10% nowrap>
      <div align="center"><FONT size=2 face="serif">55</FONT>      </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">Executive Vice President since June 2006; President&#151;BD</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">Biosciences from March 2003 to June 2006; and, prior thereto,</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">Senior Vice President&#151;Technology, Strategy and Development.</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>
<FONT size=2 face="serif">A. John Hanson</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=10% nowrap>
      <div align="center"><FONT size=2 face="serif">64</FONT>      </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">Executive Vice President since June 2006; and, prior thereto,</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=center width=19%>&nbsp;</TD>
    <TD align=center width=5%>&nbsp;</TD>
    <TD align=center width=10%>&nbsp;</TD>
    <TD align=center width=5%>&nbsp;</TD>
    <TD align=left width=60%><font size=2 face="serif">President&#151;BD Europe.</font></TD>
</TR>
<TR valign="bottom">
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>
<FONT size=2 face="serif">William A. Kozy</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=10% nowrap>
      <div align="center"><FONT size=2 face="serif">56</FONT>      </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">Executive Vice President since June 2006; President&#151;BD</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">Diagnostics from November 2003 to June 2006; President&#151;BD</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">Clinical Laboratory Solutions and Company Operations from</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">May 2002 to November 2003; and, prior thereto, Senior Vice</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">President&#151;Company Operations.</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>
<FONT size=2 face="serif">Jeffrey S. Sherman</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=10% nowrap>
      <div align="center"><FONT size=2 face="serif">53</FONT>      </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">Senior Vice President and General Counsel since June 2006;</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">Vice President and General Counsel from January 2004 to June</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">2006; and, prior thereto, Vice President and Associate General</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">Counsel of Wyeth.</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>
<FONT size=2 face="serif">Patricia B. Shrader</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=10% nowrap>
      <div align="center"><FONT size=2 face="serif">58</FONT>      </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">Senior Vice President&#151;Corporate Regulatory and External</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">Affairs since June 2006; Vice President, Corporate Regulatory</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">and External Affairs from February 2005 to June 2006; Vice</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">President, Corporate Regulatory, Public Policy and</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">Communication from March 2004 to Feburary 2005; and, prior</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=20% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=10% nowrap>	  </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=60% nowrap>
<FONT size=2 face="serif">thereto, Vice President&#151;Regulatory Affairs.</FONT>	</TD>
</TR>
</TABLE>
<BR>
<P align="center">
<FONT face="serif">14 </FONT><FONT size=1 face="serif"></FONT></P>

<HR noshade align="center" width="100%" size=4>



<P align="left" style="page-break-before:always"></P><PAGE>
<A name="page_15"></A>

<P align="center">
<B><FONT size=2 face="serif">PART II</FONT></B></P>
<P align="left">
<B><FONT size=2 face="serif">Item 5. </FONT></B><B><I><FONT size=2 face="serif">Market for Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</FONT></I></B><FONT size=2 face="serif"> </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">BD&#146;s common stock is listed on the New York Stock Exchange. As of October 31, 2008, there were approximately 8,787 shareholders of record. Additional information required by this item
appears under the caption &#147;Common Stock Prices and Dividends&#148; on page 63 of Exhibit 13, and is incorporated herein by reference. Certain other information required by this item will be contained under the captions &#147;Equity Compensation
Plan Information&#148; and &#147;Ownership of BD Stock&#148; in BD&#146;s Proxy Statement, and such information is incorporated herein by reference. </FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Issuer Repurchases of Equity Securities</FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The table below sets forth certain information regarding BD&#146;s purchases of its common stock during the fiscal quarter ended September 30, 2008. </FONT></P>
<P align="center"><B><FONT size=2 face="serif">Issuer Purchases of Equity Securities</FONT></B></P>
<TABLE border=0 width=100% cellspacing=0 cellpadding=0>

<TR valign="bottom">
	<TD align=left width=22% nowrap>	</TD>
	<TD width=7%>	</TD>
	<TD align=left width=12% nowrap>	</TD>
	<TD width=6%>	</TD>
	<TD align=left width=14% nowrap>	</TD>
	<TD width=5%>	</TD>
	<TD align=left width=16% nowrap>	</TD>
	<TD width=5%>	</TD>
	<TD align=right width=13% nowrap>
      <div align="center"><B><FONT size=2 face="serif">Maximum Number</FONT></B> </div></TD>
</TR>
<TR valign="bottom">
	<TD align=left width=22% nowrap>	</TD>
	<TD width=7%>	</TD>
	<TD align=left width=12% nowrap>	</TD>
	<TD width=6%>	</TD>
	<TD align=left width=14% nowrap>	</TD>
	<TD width=5%>	</TD>
	<TD align=center width=16% nowrap>
      <div align="center"><B><FONT size=2 face="serif">Total Number of Shares</FONT></B> </div></TD>
	<TD width=5%>	</TD>
	<TD align=center width=13% nowrap>
      <div align="center"><B><FONT size=2 face="serif">of Shares that</FONT></B> </div></TD>
</TR>
<TR valign="bottom">
	<TD align=left width=22% nowrap>	</TD>
	<TD width=7%>	</TD>
	<TD align=center width=12% nowrap>
      <div align="center"><B><FONT size=2 face="serif">Total Number</FONT></B> </div></TD>
	<TD width=6%>	</TD>
	<TD align=right width=14% nowrap>
      <div align="center"><B><FONT size=2 face="serif">Average</FONT></B> </div></TD>
	<TD width=5%>	</TD>
	<TD align=right width=16% nowrap>
      <div align="center"><B><FONT size=2 face="serif">Purchased as Part of</FONT></B> </div></TD>
	<TD width=5%>	</TD>
	<TD align=center width=13% nowrap>
      <div align="center"><B><FONT size=2 face="serif">may yet be</FONT></B> </div></TD>
</TR>
<TR valign="bottom">
	<TD align=left width=22% nowrap>
      <div align="left"><B><FONT size=2 face="serif">For the Three Months Ended</FONT></B> </div></TD>
	<TD width=7%>	</TD>
	<TD align=center width=12% nowrap>
      <div align="center"><B><FONT size=2 face="serif">of Shares</FONT></B> </div></TD>
	<TD width=6%>	</TD>
	<TD align=center width=14% nowrap>
      <div align="center"><B><FONT size=2 face="serif">Price Paid</FONT></B> </div></TD>
	<TD width=5%>	</TD>
	<TD align=right width=16% nowrap>
      <div align="center"><B><FONT size=2 face="serif">Publicly Announced</FONT></B> </div></TD>
	<TD width=5%>	</TD>
	<TD align=right width=13% nowrap>
      <div align="center"><B><FONT size=2 face="serif">Purchased Under the</FONT></B> </div></TD>
</TR>
<TR valign="bottom">
	<TD align=left width=22% nowrap style="border-bottom:1px solid #000000;">
      <div align="left"><B><FONT size=2 face="serif">September 30, 2008</FONT></B> </div></TD>
	<TD width=7%>	</TD>
	<TD align=right width=12% nowrap style="border-bottom:1px solid #000000;">
      <div align="center"><B><FONT size=2 face="serif">Purchased (1)</FONT></B> </div></TD>
	<TD width=6%>	</TD>
	<TD align=center width=14% nowrap style="border-bottom:1px solid #000000;">
      <div align="center"><B><FONT size=2 face="serif">per Share</FONT></B> </div></TD>
	<TD width=5%>	</TD>
	<TD align=right width=16% nowrap style="border-bottom:1px solid #000000;">
      <div align="center"><B><FONT size=2 face="serif">Plans or Programs (2)</FONT></B> </div></TD>
	<TD width=5%>	</TD>
	<TD align=right width=13% nowrap style="border-bottom:1px solid #000000;">
      <div align="center"><B><FONT size=2 face="serif">Plans or Programs</FONT></B> </div></TD>
</TR>
<TR valign="bottom">
	<TD align=left width=22% nowrap>
<FONT  size=2 face="serif">July 1-31, 2008</FONT>	</TD>
	<TD width=7%>&nbsp;	</TD>
	<TD align=right width=12% nowrap>
<FONT  size=2 face="serif">353,115</FONT>	</TD>
	<TD width=6%>&nbsp;	</TD>
	<TD align=center width=14% nowrap>
<FONT  size=2 face="serif">$&nbsp;85.11</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=16% nowrap style="border-bottom:0px solid #000000;">
<FONT  size=2 face="serif">350,000</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=13% nowrap>
<FONT  size=2 face="serif">6,619,514</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=22% nowrap>
<FONT  size=2 face="serif">August 1-31, 2008</FONT>	</TD>
	<TD width=7%>&nbsp;	</TD>
	<TD align=right width=12% nowrap>
<FONT  size=2 face="serif">502,790</FONT>	</TD>
	<TD width=6%>&nbsp;	</TD>
	<TD align=center width=14% nowrap>
<FONT  size=2 face="serif">$&nbsp;85.37</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=16% nowrap style="border-bottom:0px solid #000000;">
<FONT  size=2 face="serif">500,000</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=13% nowrap>
<FONT  size=2 face="serif">6,119,514</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=22% nowrap>
<FONT  size=2 face="serif">September 1-30, 2008</FONT>	</TD>
	<TD width=7%>&nbsp;	</TD>
	<TD align=right width=12% nowrap><div style="border-bottom:1px solid #000000"> <font  size=2 face="serif">263,979</font> </div></TD>
	<TD width=6%>&nbsp;	</TD>
	<TD align=center width=14% nowrap style="border-bottom:1px solid #000000;">
<FONT  size=2 face="serif">$&nbsp;87.76</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=16% nowrap style="border-bottom:1px solid #000000;">
<FONT  size=2 face="serif">263,600</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=13% nowrap style="border-bottom:1px solid #000000;">
<FONT  size=2 face="serif">5,855,914</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=center width=22% nowrap>
      <div align="left"><FONT  size=2 face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total</FONT> </div></TD>
	<TD width=7%>&nbsp;	</TD>
	<TD align=right width=12% nowrap><div style="border-bottom:3px double #000000"> <font  size=2 face="serif">1,119,884</font> </div></TD>
	<TD width=6%>&nbsp;	</TD>
	<TD align=center width=14% nowrap style="border-bottom:3px double #000000;">
<FONT  size=2 face="serif">$&nbsp;85.85</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=16% nowrap style="border-bottom:3px double #000000;">
<FONT  size=2 face="serif">1,113,600</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=13% nowrap style="border-bottom:3px double #000000;">
<FONT  size=2 face="serif">5,855,914</FONT>	</TD>
</TR>
</TABLE>
<BR>
<TABLE border=0 cellspacing=0 cellpadding=0>
<TR>
	<TD nowrap valign=top>
<FONT  size=2 face="serif">(1)</FONT>&nbsp; &nbsp; &nbsp; 	</TD>
	<TD width=100%>
<P align="left"><FONT  size=2 face="serif">Includes for the quarter 3,650 shares purchased in open market transactions by the trustees under BD&#146;s Deferred Compensation Plan and 1996 Directors&#146; Deferral Plan. Also includes
2,634 shares delivered to BD in connection with stock option exercises.</FONT></P>	</TD>
</TR>
<TR>
  <TD nowrap valign=top>&nbsp;</TD>
  <TD>&nbsp;</TD>
</TR>
<TR>
	<TD nowrap valign=top>
<FONT  size=2 face="serif">(2)</FONT>&nbsp; &nbsp; &nbsp; 	</TD>
	<TD width=100%>
<P align="left"><FONT  size=2 face="serif">These repurchases were made pursuant
    to a repurchase program for 10 million shares announced on July 24, 2007.
    A repurchase program for an additional 10 million shares was announced on
     November 25, 2008.</FONT><font  size=2 face="serif"> Neither program has
     an expiration date.</font></P>	</TD>
</TR>
</TABLE>
<P align="left">
<B><FONT  size=2 face="serif">Item 6. </FONT></B><B><I><FONT  size=2 face="serif">Selected Financial Data.</FONT></I></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT  size=2 face="serif">The information required by this item is included under the caption &#147;Ten-Year Summary of Selected Financial Data&#148; on pages 18-19 of Exhibit 13 and is incorporated
herein by reference. </FONT></P>
<P align="left">
<B><FONT  size=2 face="serif">Item 7. </FONT></B><B><I><FONT  size=2 face="serif">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.</FONT></I></B><FONT  size=2 face="serif"> </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT  size=2 face="serif">The information required by this item is included in the text contained under the caption &#147;Financial Review&#148; on pages 20-32 of Exhibit 13 and is incorporated herein by
reference. </FONT></P>
<P align="left">
<B><FONT  size=2 face="serif">Item 7A. </FONT></B><B><I><FONT  size=2 face="serif">Quantitative and Qualitative Disclosures About Market Risk.</FONT></I></B><FONT  size=2 face="serif"> </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT  size=2 face="serif">The information required
by this item is included in the text contained under the caption &#147;Financial
Instrument Market Risk&#148; on pages 23-24 of, and in notes 1 and 9 to
the consolidated financial statements contained in, Exhibit 13, and each is incorporated
herein by reference. </FONT></P>
<P align="center">
<FONT face="serif">15 </FONT><FONT size=1 face="serif"></FONT></P>

<HR noshade align="center" width="100%" size=4>



<P align="left" style="page-break-before:always"></P><PAGE>
<A name="page_16"></A>

<P align="left">
<B><FONT size=2 face="serif">Item 8. </FONT></B><B><I><FONT size=2 face="serif">Financial Statements and Supplementary Data.</FONT></I></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The information required
by this item is included on pages 33-62 of Exhibit 13 and is incorporated herein
by reference. </FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Item 9. </FONT></B><B><I><FONT size=2 face="serif">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</FONT></I></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">None.</FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Item 9A</FONT></B><B><I><FONT size=2 face="serif">. Controls and Procedures.</FONT></I></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">An evaluation was conducted by BD&#146;s management, with the participation of BD&#146;s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of
BD&#146;s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934) as of September 30, 2008. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the
design and operation of these disclosure controls and procedures were, as of the end of the period covered by this report, effective and designed to ensure that material information relating to BD and its consolidated subsidiaries would be made
known to them by others within these entities. There were no changes in BD&#146;s internal control over financial reporting during the fiscal quarter ended September 30, 2008 identified in connection with the above-referenced evaluations that has
materially affected, or is reasonably likely to materially affect, the internal control over financial reporting. </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Management&#146;s Report on Internal Control Over Financial Reporting and the Report of Independent Registered Public Accounting Firm on pages 33 and 35, respectively, of Exhibit 13 are
incorporated herein by reference. </FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Item 9B. </FONT></B><B><I><FONT size=2 face="serif">Other Information.</FONT></I></B><BR>
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Not applicable. </FONT></P>
<P align="center">
<B><FONT size=2 face="serif">PART III</FONT></B></P>
<P align="left">
<B><FONT size=2 face="serif">Item 10. </FONT></B><B><I><FONT size=2 face="serif">Directors, Executive Officers and Corporate Governance.</FONT></I></B><FONT size=2 face="serif"> </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The information relating
to directors and the Audit Committee of the BD Board of Directors required by
this item will be contained under the captions Proposal 1. &#147;Election of Directors&#148; and &#147;Board of
Directors&#151;Committee Membership and Function&#151;Audit
Committee&#148; in a definitive proxy statement involving the election of directors, which the registrant will file with the SEC not later than 120 days after September 30, 2008 (the &#147;Proxy
Statement&#148;), and such information is incorporated herein by reference. </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The information relating to executive officers required by this item is included herein in Part I under the caption &#147;Executive Officers of the Registrant.&#148; </FONT></P>
<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Certain
    other information  required by this item will be contained under the captions
    &#147;Ownership of BD Common Stock&#151;Section
    16(a) Beneficial Ownership Reporting Compliance&#148; and &#147;Corporate
    Governance&#151;Significant Governance Practices&#151;Business Conduct and
    Compliance Guide&#148; in
  BD&#146;s Proxy Statement, and such information is incorporated herein by reference. </FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Item 11. </FONT></B><B><I><FONT size=2 face="serif">Executive Compensation.</FONT></I></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The information required by this item will be contained under the captions &#147;Board of Directors&#151;Non-Management Directors&#146; Compensation,&#148; &#147;Corporate
Governance&#151;Significant Governance Practices&#151;Compensation Committee Interlocks and Insider Participation,&#148; &#147;Compensation Discussion and Analysis,&#148; &#147;Report of the Compensation and Benefits Commitee,&#148; and
&#147;Compensation of Named Executive Officers&#148; in BD&#146;s Proxy Statement, and such information is incorporated herein by reference. </FONT></P>
<P align="center">
<FONT face="serif">16 </FONT><FONT size=1 face="serif"></FONT></P>

<HR noshade align="center" width="100%" size=4>



<P align="left" style="page-break-before:always"></P><PAGE>
<A name="page_17"></A>

<P align="left">
<B><FONT size=2 face="serif">Item 12. </FONT></B><B><I><FONT size=2 face="serif">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</FONT></I></B><FONT size=2 face="serif"> </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The information required by this item will be contained under the caption &#147;Ownership of BD Common Stock&#148; in BD&#146;s Proxy Statement, and such information is incorporated herein by
reference. </FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Item 13. </FONT></B><B><I><FONT size=2 face="serif">Certain Relationships and Related Transactions, and Director Independence.</FONT></I></B><FONT size=2 face="serif"> </FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The information required by this item will be contained under the caption &#147;Corporate Governance&#151;Significant Governance Practices&#151;Director Independence/Certain Relationships and
Related Transactions&#148; in BD&#146;s Proxy Statement, and such information is incorporated herein by reference. </FONT></P>
<P align="left">
<B><FONT size=2 face="serif">Item 14. </FONT></B><B><I><FONT size=2 face="serif">Principal Accounting Fees and Services.</FONT></I></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The information required by this item will be contained under the caption &#147;Proposal 2. Ratification of Selection of Independent Registered Public Accounting Firm&#148; in BD&#146;s Proxy
Statement, and such information is incorporated herein by reference. </FONT></P>
<P align="center">
<B><FONT size=2 face="serif">PART IV</FONT></B></P>
<P align="left">
<B><FONT size=2 face="serif">Item 15.</FONT></B><B><I><FONT size=2 face="serif"> Exhibits, Financial Statement Schedules.</FONT></I></B></P>
<P align="left"><FONT size=2 face="serif">(a)</FONT>&nbsp; <I><FONT size=2 face="serif">Financial
Statements</FONT></I></P>
<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The following consolidated financial
statements of BD included in Exhibit 13 at the pages indicated in</FONT> <FONT size=2 face="serif">parentheses,
are incorporated by reference in Item 8 of this report:</FONT></P>
<UL>
<LI>
<P align="left"><FONT size=2 face="serif">Reports of Independent Registered Public Accounting Firm (pages 34-35)</FONT></P></LI>
<LI>
<P align="left"><FONT size=2 face="serif">Consolidated Statements of Income&#151;Years ended September 30, 2008, 2007 and 2006 (page 36)</FONT></P></LI>
<LI>
<P align="left"><FONT size=2 face="serif">Consolidated Statements of Comprehensive Income&#151;Years ended September 30, 2008, 2007 and 2006 (page</FONT> <FONT size=2 face="serif">37)</FONT></P></LI>
<LI>
<P align="left"><FONT size=2 face="serif">Consolidated Balance Sheets&#151;September 30, 2008 and 2007 (page 38)</FONT></P></LI>
<LI>
<P align="left"><FONT size=2 face="serif">Consolidated Statements of Cash Flows&#151;Years ended September 30, 2008, 2007 and 2006 (page 39)</FONT></P></LI>
<LI>
<P align="left"><FONT size=2 face="serif">Notes to Consolidated Financial Statements (pages 40-62)</FONT>
</LI>
</UL>

  <P align="left">
<FONT size=2 face="serif">(b) </FONT>&nbsp;<I><FONT size=2 face="serif">Financial Statement Schedules</FONT></I>
<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The following
    consolidated financial statement schedule of BD is included herein at the
    page indicated in </FONT><FONT size=2 face="serif">parentheses:</FONT>
<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Schedule II&#151;Valuation and Qualifying Accounts (page 20)</FONT>
<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">All other
    schedules for which provision is made in the applicable accounting regulations
    of  the Securities</FONT><FONT size=2 face="serif"> Exchange Act of 1934
    are not required under the related instructions or are inapplicable, and,
    therefore, have been </FONT><FONT size=2 face="serif">omitted.</FONT>
<P align="left"><FONT size=2 face="serif">(c)</FONT><I>&nbsp;<FONT size=2 face="serif">Exhibits</FONT></I>
<P align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">See the
    Exhibit Index beginning on page 19 hereof for a list of all management contracts,
    compensatory plans </FONT><FONT size=2 face="serif">and arrangements required
     by this item (Exhibit Nos. 10(a)(i) through 10(p)), and all other Exhibits
    filed or </FONT><FONT size=2 face="serif">incorporated by reference as a
    part of this report.</FONT>

<P align="center">
<FONT face="serif">17 </FONT><FONT size=1 face="serif"></FONT></P>

<HR noshade align="center" width="100%" size=4>



<P align="left" style="page-break-before:always"></P><PAGE>
<A name="page_18"></A>

<P align="center">
<B><FONT size=2 face="serif">SIGNATURES</FONT></B></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized. </FONT></P>
<TABLE border=0 width=100% cellspacing=0 cellpadding=0>
  <TR valign="bottom">
    <TD align=left nowrap>&nbsp;</TD>
    <TD colspan=2 align=left nowrap><font size=2 face="serif">BECTON, DICKINSON AND COMPANY</font></TD>
  </TR>
  <TR>
    <TD colspan=3>&nbsp;</TD>
  </TR>
  <TR valign="bottom">
    <TD align=left width=36% nowrap>&nbsp;</TD>
    <TD align=left width=5% nowrap><FONT size=2 face="serif">By:</FONT> </TD>
    <TD align=center width=59% nowrap style="border-bottom:1px solid #000000;"><FONT size=2 face="serif">/s/
        DEAN J. PARANICAS</FONT> </TD>
  </TR>
  <TR valign="bottom">
    <TD align=left width=36% nowrap>&nbsp;</TD>
    <TD align=left width=5% nowrap>&nbsp;</TD>
    <TD align=center width=59% nowrap><B><FONT size=2 face="serif">Dean J. Paranicas</FONT></B> </TD>
  </TR>
  <TR valign="bottom">
    <TD align=left width=36% nowrap>&nbsp;</TD>
    <TD align=left width=5% nowrap>&nbsp;</TD>
    <TD align=center width=59% nowrap><B><FONT size=2 face="serif">Vice President,
          Corporate Secretary</FONT></B> </TD>
  </TR>
  <TR valign="bottom">
    <TD align=left width=36% nowrap>&nbsp;</TD>
    <TD align=left width=5% nowrap>&nbsp;</TD>
    <TD align=center width=59% nowrap><B><FONT size=2 face="serif">and Public
          Policy</FONT></B> </TD>
  </TR>
</TABLE>

<P align="left">
<FONT size=2 face="serif">Dated: November 26, 2008</FONT></P>
<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on the 26th day of November, 2008 by the following persons on behalf of the registrant and in the capacities indicated.
</FONT></P>

<TABLE border=0 width=100% cellspacing=0 cellpadding=0>
<TR valign="bottom">
	<TD width=45% colspan="2" align=center nowrap>
<B><U><FONT size=2 face="serif">Name</FONT></U></B>	</TD>
	<TD width=10%>&nbsp;	</TD>
	<TD align=center width=45% nowrap>
<B><U><FONT size=2 face="serif">Capacity</FONT></U></B>	</TD>
</TR>
<TR>
	<TD colspan=4>&nbsp;	</TD>
</TR>
<TR valign="bottom">
	<TD width=45% colspan="2" align=center nowrap style="border-bottom:1px solid #000000;">
<FONT size=2 face="serif">/s/ EDWARD J. LUDWIG</FONT>	</TD>
	<TD width=10%>&nbsp;	</TD>
	<TD align=center width=45% nowrap>
<FONT  size=2 face="serif">Chairman, President and</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD width=45% colspan="2" align=left nowrap><div align="center"><B><FONT  size=2 face="serif">(Edward J. Ludwig)</FONT></B> </div></TD>
	<TD width=10%>&nbsp;	</TD>
	<TD align=center width=45% nowrap>
<FONT  size=2 face="serif">Chief Executive Officer</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD width=45% colspan="2" align=left nowrap>&nbsp;	</TD>
	<TD width=10%>&nbsp;	</TD>
	<TD align=center width=45% nowrap>
<FONT  size=2 face="serif">(Principal Executive Officer)</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD width="45%" colspan="2" align=center nowrap style="border-bottom:0px solid #000000;">&nbsp;</TD>
  <TD width="10%">&nbsp;</TD>
  <TD width="45%" align=center nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD width=45% colspan="2" align=center nowrap style="border-bottom:1px solid #000000;">
<FONT  size=2 face="serif">/s/ JOHN R. CONSIDINE</FONT>	</TD>
	<TD width=10%>&nbsp;	</TD>
	<TD align=center width=45% nowrap>
<FONT  size=2 face="serif">Vice Chairman and Chief Financial Officer</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD width=45% colspan="2" align=left nowrap><div align="center"><b><font  size=2 face="serif">(John R. Considine)</font></b> </div></TD>
	<TD width=10%>&nbsp;	</TD>
	<TD align=center width=45% nowrap>
<FONT  size=2 face="serif">(Principal Financial Officer)</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD width=45% colspan="2" align=left nowrap></TD>
	<TD width=10%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>&nbsp;	</TD>
</TR>
<TR>
	<TD colspan=4>&nbsp;	</TD>
</TR>
<TR valign="bottom">
  <TD width="45%" colspan="2" align=center nowrap style="border-bottom:0px solid #000000;">&nbsp;</TD>
  <TD width="10%">&nbsp;</TD>
  <TD width="45%" align=center nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD width=45% colspan="2" align=center nowrap style="border-bottom:1px solid #000000;">
<FONT  size=2 face="serif">/s/ WILLIAM A. TOZZI</FONT>	</TD>
	<TD width=10%>&nbsp;	</TD>
	<TD align=center width=45% nowrap>
<FONT  size=2 face="serif">Vice President&#150;Finance</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD width=45% colspan="2" align=left nowrap><div align="center"><b><font  size=2 face="serif">(William A. Tozzi)</font></b> </div></TD>
	<TD width=10%>&nbsp;	</TD>
	<TD align=center width=45% nowrap>
<FONT  size=2 face="serif">(Principal Accounting Officer)</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD width=45% colspan="2" align=left nowrap></TD>
	<TD width=10%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>&nbsp;	</TD>
</TR>
<TR>
	<TD colspan=4>&nbsp;	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=22% nowrap><div align="left"></div></TD>
	<TD align=left width=23% nowrap><font  size=2 face="serif">Basil L. Anderson*</font></TD>
	<TD width=10%>	</TD>
	<TD align=left width=45% nowrap><div align="center"><FONT  size=2 face="serif">Director</FONT> </div></TD>
</TR>
<TR valign="bottom">
	<TD width=22% align=left nowrap>&nbsp;</TD>
	<TD width=22% align=left nowrap><div align="left"><FONT  size=2 face="serif">Henry
	      P. Becton, Jr.*</FONT> </div></TD>
	<TD width=10%>	</TD>
	<TD align=left width=45% nowrap><div align="center"><FONT  size=2 face="serif">Director</FONT> </div></TD>
</TR>
<TR valign="bottom">
	<TD width=22% align=left nowrap>&nbsp;</TD>
	<TD width=22% align=left nowrap><div align="left"><FONT  size=2 face="serif">Edward
	      F. DeGraan*</FONT> </div></TD>
	<TD width=10%>	</TD>
	<TD align=left width=45% nowrap><div align="center"><FONT  size=2 face="serif">Director</FONT> </div></TD>
</TR>
<TR valign="bottom">
	<TD width=22% align=left nowrap>&nbsp;</TD>
	<TD width=22% align=left nowrap><div align="left"><FONT  size=2 face="serif">Claire
	      M. Fraser-Liggett*</FONT> </div></TD>
	<TD width=10%>	</TD>
	<TD align=left width=45% nowrap><div align="center"><FONT  size=2 face="serif">Director</FONT> </div></TD>
</TR>
<TR valign="bottom">
	<TD width=22% align=left nowrap>&nbsp;</TD>
	<TD width=22% align=left nowrap><div align="left"><FONT  size=2 face="serif">Marshall
	      O. Larsen*</FONT> </div></TD>
	<TD width=10%>	</TD>
	<TD align=left width=45% nowrap><div align="center"><FONT  size=2 face="serif">Director</FONT> </div></TD>
</TR>
<TR valign="bottom">
	<TD width=22% align=left nowrap>&nbsp;</TD>
	<TD width=22% align=left nowrap><div align="left"><FONT  size=2 face="serif">Adel
	      A.F. Mahmoud*</FONT> </div></TD>
	<TD width=10%>	</TD>
	<TD align=left width=45% nowrap><div align="center"><FONT  size=2 face="serif">Director</FONT> </div></TD>
</TR>
<TR valign="bottom">
	<TD width=22% align=left nowrap>&nbsp;</TD>
	<TD width=22% align=left nowrap><div align="left"><FONT  size=2 face="serif">Gary
	      A. Mecklenburg*</FONT> </div></TD>
	<TD width=10%>	</TD>
	<TD align=left width=45% nowrap><div align="center"><FONT  size=2 face="serif">Director</FONT> </div></TD>
</TR>
<TR valign="bottom">
	<TD width=22% align=left nowrap>&nbsp;</TD>
	<TD width=22% align=left nowrap><div align="left"><FONT  size=2 face="serif">Cathy
	      E. Minehan*</FONT> </div></TD>
	<TD width=10%>	</TD>
	<TD align=left width=45% nowrap><div align="center"><FONT  size=2 face="serif">Director</FONT> </div></TD>
</TR>
<TR valign="bottom">
	<TD width=22% align=left nowrap>&nbsp;</TD>
	<TD width=22% align=left nowrap><div align="left"><FONT  size=2 face="serif">James
	      F. Orr*</FONT> </div></TD>
	<TD width=10%>	</TD>
	<TD align=left width=45% nowrap><div align="center"><FONT  size=2 face="serif">Director</FONT> </div></TD>
</TR>
<TR valign="bottom">
	<TD width=22% align=left nowrap>&nbsp;</TD>
	<TD width=22% align=left nowrap><div align="left"><FONT  size=2 face="serif">Willard
	      J. Overlock, Jr.*</FONT> </div></TD>
	<TD width=10%>	</TD>
	<TD align=left width=45% nowrap><div align="center"><FONT  size=2 face="serif">Director</FONT> </div></TD>
</TR>
<TR valign="bottom">
	<TD width=22% align=left nowrap>&nbsp;</TD>
	<TD width=22% align=left nowrap><div align="left"><FONT  size=2 face="serif">Bertram
	      L. Scott*</FONT> </div></TD>
	<TD width=10%>	</TD>
	<TD align=left width=45% nowrap><div align="center"><FONT  size=2 face="serif">Director</FONT> </div></TD>
</TR>
<TR valign="bottom">
	<TD width=22% align=left nowrap>&nbsp;</TD>
	<TD width=22% align=left nowrap><div align="left"><FONT  size=2 face="serif">Alfred
	      Sommer*</FONT> </div></TD>
	<TD width=10%>	</TD>
	<TD align=left width=45% nowrap><div align="center"><FONT  size=2 face="serif">Director</FONT> </div></TD>
</TR>
</TABLE>

<br>
<br>
<TABLE border=0 width=100% cellspacing=0 cellpadding=0>

  <TR valign="bottom">
    <TD align=left width=36% nowrap>&nbsp;</TD>
    <TD align=left width=5% nowrap><FONT size=2 face="serif">*By:</FONT> </TD>
    <TD align=center width=59% nowrap style="border-bottom:1px solid #000000;"><FONT size=2 face="serif">/s/
        DEAN J. PARANICAS</FONT> </TD>
  </TR>
  <TR valign="bottom">
    <TD align=left width=36% nowrap>&nbsp;</TD>
    <TD align=left width=5% nowrap>&nbsp;</TD>
    <TD align=center width=59% nowrap><B><FONT size=2 face="serif">Dean J. Paranicas</FONT></B> </TD>
  </TR>
  <TR valign="bottom">
    <TD align=left width=36% nowrap>&nbsp;</TD>
    <TD align=left width=5% nowrap>&nbsp;</TD>
    <TD align=center width=59% nowrap><B><FONT  size=2 face="serif">Attorney-in-fact</FONT></B></TD>
  </TR>
</TABLE>
<p><BR>
</p>
<div align="center"><FONT face="serif">18</FONT><BR>
  <BR>

</div>
<HR noshade align="center" width="100%" size=4>



<P align="left" style="page-break-before:always"></P><PAGE>
<p><A name="page_19"></A></p>
<P align="right"><B><FONT size=2 face="serif">SCHEDULE II</FONT></B><FONT face="serif"> </FONT></P>
<P align="center"> <B><FONT face="serif">BECTON, DICKINSON AND COMPANY</FONT></B><B><FONT size=2 face="serif"> </FONT></B><br>
  <B><FONT size=2 face="serif">VALUATION AND QUALIFYING ACCOUNTS</FONT></B><B><FONT size=2 face="serif"> <br>
  Years
Ended September 30, 2008, 2007 and 2006 </FONT></B><br>
<B><FONT size=2 face="serif">(Thousands
of dollars) </FONT></B><FONT face="serif"> </FONT></P>


<TABLE border=0 width=100% cellspacing=0 cellpadding=0>
<TR valign="bottom">
	<TD align=left width=6% nowrap style="border-bottom:1px solid #000000;">	</TD>
	<TD align=center width=23% nowrap style="border-bottom:1px solid #000000;">
      <div align="center"><B><FONT size=2 face="serif">Col. A</FONT></B> </div></TD>
	<TD width=5%>	</TD>
	<TD colspan="2" align=right nowrap style="border-bottom:1px solid #000000;">

	  <div align="center"><B><FONT size=2 face="serif">Col. B</FONT></B> </div></TD>
	<TD width=5%>	</TD>
	<TD colspan="2" align=right nowrap style="border-bottom:1px solid #000000;">
      <div align="center"><B><FONT size=2 face="serif">Col. C</FONT></B> </div></TD>
	<TD width=5%>	</TD>
	<TD colspan="3" align=right nowrap style="border-bottom:1px solid #000000;">
      <div align="center"><B><FONT size=2 face="serif">Col. D</FONT></B> </div>	</TD>
	<TD width=5%>	</TD>
	<TD colspan="2" align=right nowrap style="border-bottom:1px solid #000000;">
      <div align="center"><B><FONT size=2 face="serif">Col. E</FONT></B> </div></TD>
  </TR>
<TR valign="bottom">
	<TD align=left width=6% nowrap>	</TD>
	<TD align=left width=23% nowrap>	</TD>
	<TD width=5%>	</TD>
	<TD align=right width=4% nowrap>	  </TD>
	<TD align=left width=10% nowrap>	</TD>
	<TD width=5%>	</TD>
	<TD colspan="2" align=right nowrap>
      <div align="center"><B><FONT size=2 face="serif">Additions</FONT></B> </div></TD>
	<TD width=5%>	</TD>
	<TD align=right width=2% nowrap>	</TD>
	<TD align=left width=9% nowrap>	</TD>
	<TD align=left width=3% nowrap>	</TD>
	<TD width=5%>	</TD>
	<TD align=right width=4% nowrap>	</TD>
	<TD align=left width=7% nowrap>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=6% nowrap>	</TD>
	<TD align=left width=23% nowrap>	</TD>
	<TD width=5%>	</TD>
	<TD colspan="2" align=right nowrap>

	  <div align="center"><B><FONT size=2 face="serif">Balance at</FONT></B> </div></TD>
	<TD width=5%>	</TD>
	<TD colspan="2" align=right nowrap>
      <div align="center"><B><FONT size=2 face="serif">Charged to</FONT></B> </div></TD>
	<TD width=5%>	</TD>
	<TD align=right width=2% nowrap>	</TD>
	<TD align=left width=9% nowrap>	</TD>
	<TD align=left width=3% nowrap>	</TD>
	<TD width=5%>	</TD>
	<TD colspan="2" align=right nowrap>
      <div align="center"><B><FONT size=2 face="serif">Balance at</FONT></B> </div></TD>
  </TR>
<TR valign="bottom">
	<TD width=6% height="16" align=left nowrap>	</TD>
	<TD align=left width=23% nowrap>	</TD>
	<TD width=5%>	</TD>
	<TD colspan="2" align=right nowrap>

	  <div align="center"><B><FONT size=2 face="serif">Beginning</FONT></B> </div></TD>
	<TD width=5%>	</TD>
	<TD colspan="2" align=right nowrap>
      <div align="center"><B><FONT size=2 face="serif">Costs and</FONT></B> </div></TD>
	<TD width=5%>	</TD>
	<TD colspan="3" align=right nowrap>

      <div align="center"><B><FONT size=2 face="serif">Deductions/</FONT></B> </div>	</TD>
	<TD width=5%>	</TD>
	<TD colspan="2" align=right nowrap>
      <div align="center"><B><FONT size=2 face="serif">End of</FONT></B> </div></TD>
  </TR>
<TR valign="bottom">
	<TD align=left width=6% nowrap>	</TD>
	<TD align=center width=23% nowrap style="border-bottom:1px solid #000000;">
      <div align="center"><B><FONT size=2 face="serif">Description</FONT></B> </div></TD>
	<TD width=5%>	</TD>
	<TD colspan="2" align=right nowrap style="border-bottom:1px solid #000000;">

	  <div align="center"><B><FONT size=2 face="serif">of Period</FONT></B> </div></TD>
	<TD width=5%>	</TD>
	<TD colspan="2" align=right nowrap style="border-bottom:1px solid #000000;">
      <div align="center"><B><FONT size=2 face="serif">Expenses</FONT></B> </div></TD>
	<TD width=5%>	</TD>
	<TD colspan="3" align=right nowrap style="border-bottom:1px solid #000000;">
      <div align="center"><B><FONT size=2 face="serif">Other</FONT></B> </div>	</TD>
	<TD width=5%>	</TD>
	<TD colspan="2" align=right nowrap style="border-bottom:1px solid #000000;">
      <div align="center"><B><FONT size=2 face="serif">Period</FONT></B> </div></TD>
  </TR>
<TR valign="bottom">
	<TD align=left width=6% nowrap>
<B><FONT  size=2 face="serif">2008</FONT></B>	</TD>
	<TD align=left width=23% nowrap style="border-bottom:0px solid #000000;">&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap style="border-bottom:0px double #000000;">

	  <div align="left"></div></TD>
	<TD align=left width=10% nowrap style="border-bottom:0px double #000000;">&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap style="border-bottom:0px solid #000000;">	<div align="left"></div></TD>
	<TD align=left width=8% nowrap style="border-bottom:0px solid #000000;">&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=2% nowrap style="border-bottom:0px solid #000000;">	<div align="left"></div></TD>
	<TD align=left width=9% nowrap style="border-bottom:0px solid #000000;">&nbsp;	</TD>
	<TD align=left width=3% nowrap style="border-bottom:0px solid #000000;">&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap style="border-bottom:0px solid #000000;">	<div align="left"></div></TD>
	<TD align=left width=7% nowrap style="border-bottom:0px solid #000000;">&nbsp;	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=6% nowrap>&nbsp;	</TD>
	<TD align=left width=23% nowrap>
<FONT  size=2 face="serif">Against trade receivables:</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap>

	  <div align="left"></div></TD>
	<TD align=left width=10% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap>	<div align="left"></div></TD>
	<TD align=left width=8% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=2% nowrap>	<div align="left"></div></TD>
	<TD align=left width=9% nowrap>&nbsp;	</TD>
	<TD align=left width=3% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap>	<div align="left"></div></TD>
	<TD align=left width=7% nowrap>&nbsp;	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=6% nowrap>&nbsp;	</TD>
	<TD align=left width=23% nowrap>
 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<FONT  size=2 face="serif">For doubtful accounts</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap>
      <div align="left"><FONT  size=2 face="serif">&#36;</FONT>      </div></TD>
	<TD align=right width=10% nowrap>
<FONT  size=2 face="serif">29,238</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap>
      <div align="left"><FONT  size=2 face="serif">&#36;</FONT> </div></TD>
	<TD align=right width=8% nowrap>
<FONT  size=2 face="serif">5,405</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=2% nowrap>
      <div align="left"><FONT  size=2 face="serif">&#36;</FONT> </div></TD>
	<TD align=right width=9% nowrap>
<FONT  size=2 face="serif">7,934</FONT>	</TD>
	<TD align=left width=3% nowrap>
<FONT  size=2 face="serif">(A)</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap>
      <div align="left"><FONT  size=2 face="serif">&#36;</FONT> </div></TD>
	<TD align=right width=7% nowrap>
<FONT  size=2 face="serif">26,709</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=6% nowrap>&nbsp;	</TD>
	<TD align=left width=23% nowrap>
 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<FONT  size=2 face="serif">For cash discounts</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap>

	  <div align="left">
	    <div style="border-bottom:1px solid #000000"> &nbsp;</div>
	  </div></TD>
	<TD align=right width=10% nowrap><div style="border-bottom:1px solid #000000"> <font  size=2 face="serif">10,412</font> </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap>	<div align="left">
	  <div style="border-bottom:1px solid #000000"> &nbsp;</div>
	</div></TD>
	<TD align=right width=8% nowrap><div style="border-bottom:1px solid #000000"> <font  size=2 face="serif">50,055</font> </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=2% nowrap style="border-bottom:1px solid #000000;">	<div align="left">&nbsp;</div></TD>
	<TD align=right width=9% nowrap style="border-bottom:1px solid #000000;">
<FONT  size=2 face="serif">51,562</FONT>	</TD>
	<TD align=left width=3% nowrap style="border-bottom:1px solid #000000;">&nbsp; </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap style="border-bottom:1px solid #000000;">	<div align="left">&nbsp;</div></TD>
	<TD align=right width=7% nowrap style="border-bottom:1px solid #000000;">
<FONT  size=2 face="serif">8,905</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=6% nowrap>&nbsp;	</TD>
	<TD align=left width=23% nowrap>
 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<FONT  size=2 face="serif">Total</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap style="border-bottom:3px double #000000;">
      <div align="left"><FONT  size=2 face="serif">&#36;</FONT>      </div></TD>
	<TD align=right width=10% nowrap style="border-bottom:3px double #000000;">
<FONT  size=2 face="serif">39,650</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap style="border-bottom:3px double #000000;">
      <div align="left"><FONT  size=2 face="serif">&#36;</FONT> </div></TD>
	<TD align=right width=8% nowrap style="border-bottom:3px double #000000;">
<FONT  size=2 face="serif">55,460</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=2% nowrap style="border-bottom:3px double #000000;">
      <div align="left"><FONT  size=2 face="serif">&#36;</FONT> </div></TD>
	<TD align=right width=9% nowrap style="border-bottom:3px double #000000;">
<FONT  size=2 face="serif">59,496</FONT>	</TD>
	<TD align=left width=3% nowrap style="border-bottom:3px double #000000;">&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap style="border-bottom:3px double #000000;">
      <div align="left"><FONT  size=2 face="serif">&#36;</FONT> </div></TD>
	<TD align=right width=7% nowrap style="border-bottom:3px double #000000;">
<FONT  size=2 face="serif">35,614</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=6% nowrap>
<B><FONT  size=2 face="serif">2007</FONT></B>	</TD>
	<TD align=left width=23% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap style="border-bottom:0px solid #000000;">

	  <div align="left"></div></TD>
	<TD align=left width=10% nowrap style="border-bottom:0px solid #000000;">&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap>	<div align="left"></div></TD>
	<TD align=left width=8% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=2% nowrap>	<div align="left"></div></TD>
	<TD align=left width=9% nowrap>&nbsp;	</TD>
	<TD align=left width=3% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap>	<div align="left"></div></TD>
	<TD align=left width=7% nowrap>&nbsp;	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=6% nowrap>&nbsp;	</TD>
	<TD align=left width=23% nowrap>
<FONT  size=2 face="serif">Against trade receivables:</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap style="border-bottom:0px double #000000;">

	  <div align="left"></div></TD>
	<TD align=left width=10% nowrap style="border-bottom:0px double #000000;">&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap style="border-bottom:0px solid #000000;">	<div align="left"></div></TD>
	<TD align=left width=8% nowrap style="border-bottom:0px solid #000000;">&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=2% nowrap style="border-bottom:0px solid #000000;">	<div align="left"></div></TD>
	<TD align=left width=9% nowrap style="border-bottom:0px solid #000000;">&nbsp;	</TD>
	<TD align=left width=3% nowrap style="border-bottom:0px solid #000000;">&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap style="border-bottom:0px solid #000000;">	<div align="left"></div></TD>
	<TD align=left width=7% nowrap style="border-bottom:0px solid #000000;">&nbsp;	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=6% nowrap>&nbsp;	</TD>
	<TD align=left width=23% nowrap>
 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<FONT  size=2 face="serif">For doubtful accounts</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap>
      <div align="left"><FONT  size=2 face="serif">&#36;</FONT>      </div></TD>
	<TD align=right width=10% nowrap>
<FONT  size=2 face="serif">28,440</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap>
      <div align="left"><FONT  size=2 face="serif">&#36;</FONT> </div></TD>
	<TD align=right width=8% nowrap>
<FONT  size=2 face="serif">2,550</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=2% nowrap>
      <div align="left"><FONT  size=2 face="serif">&#36;</FONT> </div></TD>
	<TD align=right width=9% nowrap>
<FONT  size=2 face="serif">1,752</FONT>	</TD>
	<TD align=left width=3% nowrap>
<FONT  size=2 face="serif">(A)</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap>
      <div align="left"><FONT  size=2 face="serif">&#36;</FONT> </div></TD>
	<TD align=right width=7% nowrap>
<FONT  size=2 face="serif">29,238</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=6% nowrap>&nbsp;	</TD>
	<TD align=left width=23% nowrap>
 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<FONT  size=2 face="serif">For cash discounts</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap style="border-bottom:1px solid #000000;">

	  <div align="left">&nbsp;</div></TD>
	<TD align=right width=10% nowrap style="border-bottom:1px solid #000000;">
<FONT  size=2 face="serif">9,816</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap>	<div align="left">
	  <div style="border-bottom:1px solid #000000"> &nbsp;</div>
	</div></TD>
	<TD align=right width=8% nowrap><div style="border-bottom:1px solid #000000"> <font  size=2 face="serif">39,575</font> </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=2% nowrap style="border-bottom:1px solid #000000;">	<div align="left">&nbsp;</div></TD>
	<TD align=right width=9% nowrap style="border-bottom:1px solid #000000;">
<FONT  size=2 face="serif">38,979</FONT>	</TD>
	<TD align=left width=3% nowrap style="border-bottom:1px solid #000000;">&nbsp; </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap style="border-bottom:1px solid #000000;">	<div align="left">&nbsp;</div></TD>
	<TD align=right width=7% nowrap style="border-bottom:1px solid #000000;">
<FONT  size=2 face="serif">10,412</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=6% nowrap>&nbsp;	</TD>
	<TD align=left width=23% nowrap>
 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<FONT  size=2 face="serif">Total</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap style="border-bottom:3px double #000000;">
      <div align="left"><FONT  size=2 face="serif">&#36;</FONT>      </div></TD>
	<TD align=right width=10% nowrap style="border-bottom:3px double #000000;">
<FONT  size=2 face="serif">38,256</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap style="border-bottom:3px double #000000;">
      <div align="left"><FONT  size=2 face="serif">&#36;</FONT> </div></TD>
	<TD align=right width=8% nowrap style="border-bottom:3px double #000000;">
<FONT  size=2 face="serif">42,125</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=2% nowrap style="border-bottom:3px double #000000;">
      <div align="left"><FONT  size=2 face="serif">&#36;</FONT> </div></TD>
	<TD align=right width=9% nowrap style="border-bottom:3px double #000000;">
<FONT  size=2 face="serif">40,731</FONT>	</TD>
	<TD align=left width=3% nowrap style="border-bottom:3px double #000000;">&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap style="border-bottom:3px double #000000;">
      <div align="left"><FONT  size=2 face="serif">&#36;</FONT> </div></TD>
	<TD align=right width=7% nowrap style="border-bottom:3px double #000000;">
<FONT  size=2 face="serif">39,650</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=6% nowrap>
<B><FONT  size=2 face="serif">2006</FONT></B>	</TD>
	<TD align=left width=23% nowrap style="border-bottom:0px solid #000000;">&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap style="border-bottom:0px double #000000;">

	  <div align="left"></div></TD>
	<TD align=left width=10% nowrap style="border-bottom:0px double #000000;">&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap style="border-bottom:0px solid #000000;">	<div align="left"></div></TD>
	<TD align=left width=8% nowrap style="border-bottom:0px solid #000000;">&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=2% nowrap style="border-bottom:0px solid #000000;">	<div align="left"></div></TD>
	<TD align=left width=9% nowrap style="border-bottom:0px solid #000000;">&nbsp;	</TD>
	<TD align=left width=3% nowrap style="border-bottom:0px solid #000000;">&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap style="border-bottom:0px solid #000000;">	<div align="left"></div></TD>
	<TD align=left width=7% nowrap style="border-bottom:0px solid #000000;">&nbsp;	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=6% nowrap>&nbsp;	</TD>
	<TD align=left width=23% nowrap>
<FONT  size=2 face="serif">Against trade receivables:</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap>

	  <div align="left"></div></TD>
	<TD align=left width=10% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap>	<div align="left"></div></TD>
	<TD align=left width=8% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=2% nowrap>	<div align="left"></div></TD>
	<TD align=left width=9% nowrap>&nbsp;	</TD>
	<TD align=left width=3% nowrap>&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap>	<div align="left"></div></TD>
	<TD align=left width=7% nowrap>&nbsp;	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=6% nowrap>&nbsp;	</TD>
	<TD align=left width=23% nowrap>
 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<FONT  size=2 face="serif">For doubtful accounts</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap>
      <div align="left"><FONT  size=2 face="serif">&#36;</FONT>      </div></TD>
	<TD align=right width=10% nowrap>
<FONT  size=2 face="serif">33,384</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap>
      <div align="left"><FONT  size=2 face="serif">&#36;</FONT> </div></TD>
	<TD align=right width=8% nowrap>
<FONT  size=2 face="serif">1,115</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=2% nowrap>
      <div align="left"><FONT  size=2 face="serif">&#36;</FONT> </div></TD>
	<TD align=right width=9% nowrap>
<FONT  size=2 face="serif">6,059</FONT>	</TD>
	<TD align=left width=3% nowrap>
<FONT  size=2 face="serif">(A)</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap>
      <div align="left"><FONT  size=2 face="serif">&#36;</FONT> </div></TD>
	<TD align=right width=7% nowrap>
<FONT  size=2 face="serif">28,440</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=6% nowrap>&nbsp;	</TD>
	<TD align=left width=23% nowrap>
 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<FONT  size=2 face="serif">For cash discounts</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap>

	  <div align="left">
	    <div style="border-bottom:1px solid #000000"> &nbsp;</div>
	  </div></TD>
	<TD align=right width=10% nowrap><div style="border-bottom:1px solid #000000"> <font  size=2 face="serif">14,225</font> </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap>	<div align="left">
	  <div style="border-bottom:1px solid #000000"> &nbsp;</div>
	</div></TD>
	<TD align=right width=8% nowrap><div style="border-bottom:1px solid #000000"> <font  size=2 face="serif">36,161</font> </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=2% nowrap style="border-bottom:1px solid #000000;">	<div align="left">&nbsp;</div></TD>
	<TD align=right width=9% nowrap style="border-bottom:1px solid #000000;">
<FONT  size=2 face="serif">40,570</FONT>	</TD>
	<TD align=left width=3% nowrap style="border-bottom:1px solid #000000;">&nbsp; </TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap style="border-bottom:1px solid #000000;">	<div align="left">&nbsp;</div></TD>
	<TD align=right width=7% nowrap style="border-bottom:1px solid #000000;">
<FONT  size=2 face="serif">9,816</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=6% nowrap>&nbsp;	</TD>
	<TD align=left width=23% nowrap>
 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<FONT  size=2 face="serif">Total</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap style="border-bottom:3px double #000000;">
      <div align="left"><FONT  size=2 face="serif">&#36;</FONT>      </div></TD>
	<TD align=right width=10% nowrap style="border-bottom:3px double #000000;">
<FONT  size=2 face="serif">47,609</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap style="border-bottom:3px double #000000;">
      <div align="left"><FONT  size=2 face="serif">&#36;</FONT> </div></TD>
	<TD align=right width=8% nowrap style="border-bottom:3px double #000000;">
<FONT  size=2 face="serif">37,276</FONT>	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=2% nowrap style="border-bottom:3px double #000000;">
      <div align="left"><FONT  size=2 face="serif">&#36;</FONT> </div></TD>
	<TD align=right width=9% nowrap style="border-bottom:3px double #000000;">
<FONT  size=2 face="serif">46,629</FONT>	</TD>
	<TD align=left width=3% nowrap style="border-bottom:3px double #000000;">&nbsp;	</TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=right width=4% nowrap style="border-bottom:3px double #000000;">
      <div align="left"><FONT  size=2 face="serif">&#36;</FONT> </div></TD>
	<TD align=right width=7% nowrap style="border-bottom:3px double #000000;">
<FONT  size=2 face="serif">38,256</FONT>	</TD>
</TR>
</TABLE>
<BR>
<P align="left"><FONT  size=2 face="serif">(A) Accounts written off.</FONT><FONT  size=1 face="serif"> </FONT></P>
<P align="center"><FONT face="serif">19 </FONT><FONT size=1 face="serif"></FONT></P>
<P align="left">&nbsp;</P>
<P align="left">&nbsp;</P>

<HR noshade align="center" width="100%" size=4>



<P align="left" style="page-break-before:always"></P><PAGE>
<p><A name="page_20"></A></p>
<p align="center"><B><FONT size=2 face="serif">EXHIBIT INDEX</FONT></B></p>
<TABLE border=0 width=100% cellspacing=0 cellpadding=0>

<TR valign="bottom">
	<TD align=center nowrap>
      <div align="center"><B><FONT size=2 face="serif">Exhibit</FONT></B> </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>&nbsp;	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>&nbsp;	</TD>
</TR>
<TR valign="bottom">
	<TD align=center nowrap style="border-bottom:1px solid #000000;">
      <div align="center"><B><FONT size=2 face="serif">Number</FONT></B> </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=center width=45% nowrap style="border-bottom:1px solid #000000;">
<B><FONT size=2 face="serif">Description</FONT></B>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=center width=38% nowrap style="border-bottom:1px solid #000000;">
<B><FONT size=2 face="serif">Method of Filing</FONT></B>	</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">3(a)(i)</FONT> </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Restated Certificate of Incorporation, as amended</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Incorporated by reference to Exhibit 3(a) to the</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">January 22, 1990</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">registrant&#146;s Annual Report on Form 10-K for fiscal</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>&nbsp;	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">year ended September 30, 1990</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">3(a)(ii)</FONT> </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Amendment to the Restated Certificate of</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Incorporated by reference to Exhibit 3(a) to the</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Incorporation, as of August 5, 1996</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">registrant&#146;s Quarterly Report on Form 10-Q for
the</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>&nbsp;	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">period ended June 30, 1996</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">3(a)(iii)</FONT> </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Amendment to the Restated Certificate of</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Incorporated by reference to Exhibit 3(b) to the</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Incorporation, as of August 10, 1998</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">registrant&#146;s Quarterly Report on Form 10-Q for
the</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>&nbsp;	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">period ended June 30, 1998</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">3(b)</FONT> </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">By-Laws, as amended and restated as of</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Incorporated by reference to Exhibit 3.1 to the</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">September 30, 2008</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">registrant&#146;s Current Report on Form 8-K dated</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>&nbsp;	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">September 30, 2008</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">4(d)</FONT> </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Indenture, dated as of March 1, 1997, between the</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Incorporated by reference to Exhibit 4(a) to Form</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">registrant and The Chase Manhattan Bank (now</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">8-K filed by the registrant on July 31, 1997</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">JPMorgan Chase Bank)</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>&nbsp;	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">The registrant hereby agrees to furnish to the</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>&nbsp;	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Commission upon request a copy of any other</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>&nbsp;	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">instruments which define the rights of holders of</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>&nbsp;	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">long-term debt of the registrant.</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>&nbsp;	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">10(a)(i)</FONT> </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Form of Employment Agreement with executive</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Incorporated by reference to Exhibit 10(a)(iii) to</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">officers relating to employment following a change</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">the registrant&#146;s Annual Report on Form 10-K for</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">of control of the registrant</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">the fiscal year ended September 30, 2005</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">10(a)(ii)</FONT> </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Form of Employment Agreement with corporate</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Incorporated by reference to Exhibit 10(a)(iv) to</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">officers (other than executive officers) relating to</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">the registrant&#146;s Annual Report on Form 10-K for</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">employment following a change of control of the</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">the fiscal year ended September 30, 2005</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">registrant</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>&nbsp;	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">10(b)</FONT> </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Stock Award Plan, as amended and restated as of</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Incorporated by reference to Exhibit 10(a) to the</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">January 1, 2006</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">registrant&#146;s Quarterly Report on Form 10-Q for the</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>&nbsp;	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">period ended February 8, 2006</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">10(c)</FONT> </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Performance Incentive Plan, as amended and restated</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Incorporated by reference to Exhibit 10(c) to the</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">September 30, 2008</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">registrant&#146;s Current Report on Form 8-K for the</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>&nbsp;	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">dated September 30, 2008</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">10(d)(i)</FONT> </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Deferred Compensation and Retirement Benefit Restoration</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Filed with this report</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Plan, as amended and restated as of November 26,</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>&nbsp;	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">2008</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>&nbsp;	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">10(d)(ii)</FONT> </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">1996 Directors&#146; Deferral Plan, as amended and
restated </FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Filed with this report</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">as of November 26, 2008</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>&nbsp;	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">10(f)(ii)</FONT> </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Employee Participation Agreement dated November</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Incorporated by reference to Exhibit 10(i)(iii) to</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">27, 2000 between the registrant and John R.</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">the registrant&#146;s Annual Report on Form 10-K for</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Considine</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">the period ended September 30, 2000</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">10(f)(ii)</FONT> </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Agreement dated December 18, 2000 between the</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Incorporated by reference to Exhibit 10(i)(iv) to</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">registrant and John R. Considine</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">the registrant&#146;s Annual Report on Form 10-K for</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>&nbsp;	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">the period ended September 30, 2000</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">10(g)(i)</FONT> </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">1994 Restricted Stock Plan for Non Employee</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Incorporated by reference to Exhibit A to the</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Directors</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">registrant&#146;s Proxy Statement dated January 5, 1994</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">10(g)(ii)</FONT> </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Amendment to the 1994 Restricted Stock Plan for</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Incorporated by reference to Exhibit 10(j)(ii) to the</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Non-Employee Directors as of November 26, 1996</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">registrant&#146;s Annual Report on Form 10-K for the</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>&nbsp;	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">fiscal year ended September 30, 1996</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">10(h)(i)</FONT> </div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">1995 Stock Option Plan, as amended and restated</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Incorporated by reference to Exhibit 10(k) to the</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=8% nowrap>	<div align="left"></div></TD>
	<TD width=5%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">January 27, 1998</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">registrant&#146;s Annual Report on Form 10-K for the</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap><FONT size=2 face="serif">fiscal year ended September
    30, 1998</FONT></TD>
</TR>
</TABLE>
<p>&nbsp;</p>
<p align="center"><font face="serif">20</font><BR>
</p>
<HR noshade align="center" width="100%" size=4>



<P align="left" style="page-break-before:always"></P><PAGE>
<A name="page_21"></A>

<TABLE border=0 width=100% cellspacing=0 cellpadding=0>

<TR valign="bottom">
	<TD align=center width=9% nowrap>
      <div align="center"><B><FONT size=2 face="serif">Exhibit</FONT></B> </div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>&nbsp;	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>&nbsp;	</TD>
</TR>
<TR valign="bottom">
	<TD align=center width=9% nowrap style="border-bottom:1px solid #000000;">
      <div align="center"><B><FONT size=2 face="serif">Number</FONT></B> </div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=center width=45% nowrap style="border-bottom:1px solid #000000;">
<B><FONT size=2 face="serif">Description</FONT></B>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=right width=38% nowrap style="border-bottom:1px solid #000000;">
      <div align="center"><B><FONT size=2 face="serif">Method of Filing</FONT></B> </div></TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">10(h)(ii)</FONT> </div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Amendments dated as of April 24, 2000 to the 1995</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Incorporated by reference to Exhibit 10(k) to the</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Stock Option Plan, as amended and restated January</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">registrant&#146;s Quarterly Report on Form 10-Q for</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">27, 1998</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">the period ended June 30, 2000</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">10(i)(i)</FONT> </div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">1998 Stock Option Plan</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Incorporated by reference to Exhibit 10.1 to the</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>&nbsp;	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">registrant&#146;s Quarterly Report on Form 10-Q/A for</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>&nbsp;	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">the period ended March 31, 1998</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">10(i)(ii)</FONT> </div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Amendments dated as of April 24, 2000 to the 1998</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Incorporated by reference to Exhibit 10(l) to the</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Stock Option Plan</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">registrant&#146;s Quarterly Report on Form 10-Q for</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>&nbsp;	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">the period ended June 30, 2000</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">10(j)</FONT> </div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Australian, French and Spanish addenda to the</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Incorporated by reference to Exhibit 10(m) to the</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Becton, Dickinson and Company Stock Option Plans</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">registrant&#146;s Annual Report on Form 10-K for the</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>&nbsp;	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">fiscal year ended September 30, 1998</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">10(k)</FONT> </div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Indian addendum to the Becton, Dickinson and</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Incorporated by reference to Exhibit 10(n) to</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Company Stock Option Plans</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">registrant&#146;s Annual Report on Form 10-K for the</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>&nbsp;	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">fiscal year ended September 30, 1999</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">10(l)</FONT> </div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">China and Japan addenda to Becton, Dickinson and</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Incorporated by reference to Exhibit 10(n)(i) to</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Company Stock Option Plans</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">registrant&#146;s Annual Report on Form 10-K for the</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>&nbsp;	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">fiscal year ended September 30, 2002</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">10(m)(i)</FONT> </div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Non-Employee Directors 2000 Stock Option Plan</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Incorporated by reference to Exhibit 10(o) to the</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>&nbsp;	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">registrant&#146;s Quarterly Report on Form 10-Q for</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>&nbsp;	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">the period ended March 31, 2000</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">10(m)(ii)</FONT> </div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Amendments dated as of April 24, 2000 to the Non-</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Incorporated by reference to Exhibit 10(o) to the</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Employee Directors 2000 Stock Option Plan</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">registrant&#146;s Quarterly Report on Form 10-Q for</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>&nbsp;	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">the period ended June 30, 2000</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">10(n)</FONT> </div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">2002 Stock Option Plan</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Incorporated by reference to Appendix A to the</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>&nbsp;	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">registrant&#146;s Proxy Statement dated January 2, 2002</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">10(o)</FONT> </div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">2004 Employee and Director Equity-Based</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Filed with this report</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Compensation Plan, as amended and restated as of</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>&nbsp;	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">November 25, 2008</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>&nbsp;	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">10(p)</FONT> </div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Terms of Awards under 2004 Employee and Director</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap><FONT size=2 face="serif">Filed with this report</FONT> </TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Equity-Based Compensation Plan</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>&nbsp;	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">10(q)</FONT> </div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Amended and Restated Aircraft Time Sharing</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Incorporated by reference to Exhibit 10(r) to the</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Agreement between Becton, Dickinson and Company</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">registrant&#146;s Annual Report on Form 10-K for the</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">and Edward J. Ludwig dated as of September 22,</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">fiscal year ended September 30, 2006</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">2006</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>&nbsp;	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right nowrap>
      <div align="left"><FONT size=2 face="serif">10(r)</FONT> </div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Amended and Restated Five-Year Credit Agreement,</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Incorporated by reference to Exhibit 10(d) of the</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">dated as of August 13, 2004 among the registrant and</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">registrant&#146;s Quarterly Report on Form 10-Q for</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">the banks named therein</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">the period ended June 30, 2004</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right width=9% nowrap>
      <div align="left"><FONT size=2 face="serif">13</FONT> </div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Portions of the registrant&#146;s Annual Report to</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Filed with this report</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Shareholders for fiscal year 2008</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>&nbsp;	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right width=9% nowrap>
      <div align="left"><FONT size=2 face="serif">21</FONT> </div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Subsidiaries of the registrant</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Filed with this report</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right width=9% nowrap>
      <div align="left"><FONT size=2 face="serif">23</FONT> </div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Consent of independent registered public accounting</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Filed with this report</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">firm</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>&nbsp;	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right width=9% nowrap>
      <div align="left"><FONT size=2 face="serif">24</FONT> </div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Power of Attorney</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Filed with this report</FONT>	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right width=9% nowrap>
      <div align="left"><FONT size=2 face="serif">31</FONT> </div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Certifications of Chief Executive Officer and Chief</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Filed with this report</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Financial Officer, pursuant to SEC Rule 13(a)-14(a)</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>&nbsp;	</TD>
</TR>
<TR valign="bottom">
  <TD align=right nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align=left nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
	<TD align=right width=9% nowrap>
      <div align="left"><FONT size=2 face="serif">32</FONT> </div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Certifications of Chief Executive Officer and Chief</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>
<FONT size=2 face="serif">Filed with this report</FONT>	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">Financial Officer, pursuant to Section 1350 of Chapter</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>&nbsp;	</TD>
</TR>
<TR valign="bottom">
	<TD align=left width=9% nowrap>	<div align="left"></div></TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=45% nowrap>
<FONT size=2 face="serif">63 of Title 18 of the U.S. Code</FONT>	</TD>
	<TD width=4%>&nbsp;	</TD>
	<TD align=left width=38% nowrap>&nbsp;	</TD>
</TR>
</TABLE>
<p>&nbsp;</p>
<p align="center"><FONT face="serif">21</FONT><BR>
</p>
<HR noshade align="center" width="100%" size=4>



<P align="left" style="page-break-before:always"></P><PAGE>
<A name="page_22"></A>

<P align="left">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Copies of any Exhibits not accompanying this Form 10-K are available at a charge of 25 cents per page by contacting: Investor Relations, Becton, Dickinson and Company, 1 Becton Drive, Franklin
Lakes, New Jersey 07417-1880, Phone: 1-800-284-6845. </FONT></P>
<P align="left">&nbsp;</P>
<P align="left">&nbsp;</P>
<P align="left">&nbsp;</P>
<P align="center"><FONT face="serif">22 </FONT><FONT size=1 face="serif"></FONT></P>
<HR noshade align="center" width="100%" size=4>


</BODY>

</HTML>

</TEXT>
</DOCUMENT>
